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RIASSUNTO 
Le tecnologie di Next Generation Sequencing (NGS) consentono di analizzare 
contemporaneamente più geni e più campioni in un’unica corsa di sequenziamento. In questo 
modo potrebbe essere possibile ridurre i tempi e i costi di analisi di tutte quelle patologie 
caratterizzate da elevata eterogeneità genetica e fenotipica, la cui caratterizzazione risulta 
essere spesso complessa e dispendiosa.  
 Al fine di elaborare un nuovo algoritmo diagnostico che consenta la rapida elaborazione di 
una diagnosi molecolare di tali patologie, abbiamo deciso di validare una tra le più innovative 
tecnologie NGS attualmente in commercio, la metodica Ion Torrent, su due differenti malattie, 
entrambe caratterizzate da eterogeneità genetica. l’anemia di Fanconi (FA) e le piastrinopenie 
ereditarie (IT). 
Siccome la FA è una patologia meglio caratterizzata rispetto alle IT, durante la prima fase di 
questo lavoro di tesi abbiamo analizzato 30 campioni (25 dei quali già precedentemente 
analizzati con sequenziamento Sanger), di cui 2 wild type e 28 affetti. In seguito all’esclusione 
dalla nostra analisi di 2 campioni FA a causa di una bassa qualità di sequenziamento, abbiamo 
determinato la sensibilità (95%) e la specificità (100%) della nuova metodica confrontando i 
dati di sequenziamento Ion Torrent e quelli Sanger a nostra disposizione. Inoltre, utilizzando i 
dati di copertura della sequenza, abbiamo messo a punto un’analisi statistica volta 
all’identificazione delle Copy Number Variation (CNV), confermando le delezioni a carico del 
gene FANCA presenti in 5 pazienti. Abbiamo quindi caratterizzato 25 dei 26 pazienti 
analizzati, identificando inoltre 2 casi con mutazioni nei rari gruppi di complementazione 
FANCF e FANCL e 10 mutazioni in loci differenti dai geni causativi. Poiché non escludiamo 
la possibilità che un nuovo gene possa essere coinvolto nella patologia, riteniamo che l’unico 
paziente ancora privo di diagnosi molecolare possa essere un buon candidato per lo studio 
dell’esoma. Infine, avvalendoci dei buoni risultati ottenuti, abbiamo elaborato un nuovo 
processo diagnostico con il quale identificare in modo semplice e rapido sia le mutazioni sia le 
CNV a carico dei 16 geni coinvolti nella FA. 
 Nella seconda parte del nostro studio, abbiamo verificato se l’applicazione di tale algoritmo 
possa essere estesa anche ad altre patologie ad elevata eterogeneità genetica. Per questo 
motivo abbiamo analizzato 21 campioni affetti da piastrinopenie ereditarie, già 
precedentemente analizzati mediante sequenziamento Sanger. Grazie all’algoritmo proposto 
abbiamo potuto selezionare tra le 2225 varianti identificate le 75 (56 differenti) che sono 
risultate essere potenzialmente patogenetiche in base alla loro frequenza nella popolazione 
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(MAF<0.01), alla loro presenza nei database di mutazione e all’analisi bioinformatica di 
patogenicità. Trenta (27 differenti) di queste varianti sono state confermate mediante 
sequenziamento Sanger, di cui in particolare 14 (12 differenti) presenti in geni diversi da quelli 
causativi. Alla luce di questo dato si rendono necessari studi funzionali su tali varianti al fine 
di comprendere i meccanismi molecolari alla base delle piastrinopenie ereditarie. Infine, 
utilizzando l’algoritmo proposto, è stato possibile confermare la diagnosi molecolare in 17 dei 
21 pazienti IT, compresi i 2 affetti da trombocitopenia con assenza del radio (TAR) e portatori 
di una delezione sul cromosoma 1q21.1. I restanti 4 alleli mutati non sono stati identificati a 
causa di una bassa copertura di sequenziamento.  
 In conclusione, in base ai dati raccolti sui campioni affetti da FA e IT, possiamo affermare 
che la tecnologia di sequenziamento Ion Torrent e l’algoritmo diagnostico da noi proposto 
sono degli strumenti utili per ottenere una diagnosi molecolare completa, veloce ed 
economica. 
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ABSTRACT 
Next Generation Sequencing (NGS) technologies, such the Ion Torrent platform, could allow 
to simplify the diagnostic process of diseases characterized by an high genetic and phenotypic 
heterogeneity, because of the possibility to sequence simultaneously more genes and more 
patients in a single sequencing run. In order to develop a new diagnostic algorithm for rapid 
molecular diagnosis of these disorders, we have applied the Ion Torrent technology on two 
different genetically heterogeneous diseases, Fanconi anemia (FA) and inherited 
thrombocytopenias (IT).  Since FA is a disorder better characterized than ITs, we first 
validated the Ion torrent technology on 30 samples (2 wild type and 28 FA), 25 of which were 
already analyzed with Sanger sequencing. Because of their low sequencing quality, we have 
excluded from this type of analysis 2 of the 28 FA samples. Then, comparing Ion Torrent and 
Sanger sequencing data, we have evaluated the sensitivity (95%) and the specificity (100%) of 
Ion Torrent technology. Moreover, in order to detect copy number variations (CNVs) in FA 
genes, we have improved a statistical analysis based on coverage sequencing data, confirming 
the presence of large intragenic deletions on FANCA in 5 patients. In summary we have 
characterized 25 of the 26 FA patients analyzed, identifying also 4 mutant alleles in the rare 
complementation group FANCL and FANCF and 10 mutations in loci different from genes 
causing the disease. Since we cannot exclude that new genes are involved in FA, the only 
patient without any mutation identified is suitable for whole exome analysis. Taking advantage 
from these good sequencing data, we have developed a diagnostic algorithm that combines the 
identification of both point mutations and CNVs. In order to verify if this new diagnostic 
process could be applied also to other genetically heterogeneous diseases, we have analyzed 
21 IT patients, already characterized by Sanger sequencing. Among the 2225 variants 
identified by Ion torrent technology, using this new approach, we have select those (N=75, 56 
different) potentially pathogenetic because of their frequency (MAF<0.01), or of their 
presence in IT mutation database o because of bioinformatics analysis. Thirty of these variants 
were confirmed by Sanger sequencing, 14 (12 different) of which localized in loci different 
from the gene causing the disease. It would be interesting to carry out functional studies on 
these additional variants to unravel the molecular basis of ITs. In summary we were able to 
characterized 17 of the 21 IT patients, including 2 patients with deletions in RBM8A 
(Thrombocytopenia and Absent Radii syndrome, TAR). The remaining 4 mutant alleles were 
not detected because of a low sequencing coverage. 
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In conclusion, according to our data, we can consider the Ion Torrent technology and in 
particular the diagnostic algorithm proposed in our study, as a feasible approaches for the 
study of diseases characterized by high genetic and phenotypic heterogeneity. 
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INTRODUCTION 
The high genetic heterogeneity that characterizes human diseases has important implications 
in gene discovery and in development of molecular diagnostic protocols (McClellan and King, 
2010). Because of the high cost of Sanger sequencing, up to now a lot of different 
methodologies, such as genome-wide association studies or SNP-array analysis, were 
performed to discover unknown loci associated with the disease. However the development of 
Next Generation Sequencing technologies (NGS) has changed the comprehensiveness of 
human genetic analysis and significantly reduced the costs associated with sequencing 
(Johnsen et al, 2013). 
 Before sequencing, all currently available platforms require different steps of DNA sample 
processing, which consists of generation of a target library (Buermans and Dunnen, 2014). 
Among the different sequencing platforms, one of the most innovative is the Ion Torrent 
technology because is unique in detecting the slight change in pH that takes place during the 
DNA synthesis (Rothberg et al, 2011), avoiding the need of optical system and reducing the 
time and the cost of sequencing (Loman et al., 2012). 
ION TORRENT TECHNOLOGY  
Ion Torrent technology is based on chips with a highly dense microwell array, below which 
there is a layer of Ion-Sensitive Field-Effect Transistor (ISFET), sensor elements that are able 
to convert a chemical signal (pH changes) into a digital one (Rothberg et al, 2011). Each 
microwell acts as an individual DNA polymerization reaction chamber, containing a bead with 
million copies of a single DNA fragment to sequence. The sequencing chemistry is a simple 
process: each fragment is single-stranded and bound with primer and DNA polymerase. 
Sequencing reaction begins when one of the four nucleotide (dNTP) flows into the well. To 
distinguish the different dNTPs, the single bases are added in a predefined flow order and 
when one of it is incorporated into the nascent strand, a proton (H+) is released. The release of 
H+ is detected as a change in the pH within the sensor wells, that is converted to a voltage 
change signal. This electric input is then digitized by off-chip electronics. Finally, a signal-
processing software converts the full series of raw-data of a single well into a sequencing read 
(Figure 1A). Since the technology is based on pH change detection, Ion Torrent platform is the 
only commercially available chemistry that uses entirely natural nucleotides. Moreover due to 
the lack of the time consuming imaging, a sequencing run can be completed within 4 hours 
(Rothberg et al, 2011; Meriman et al., 2012; Buermans and Dunnen, 2014). 
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Figure 1: Ion Torrent sequencing technology. A) A simplified drawing of a well, a bead containing DNA 
template and the underlying sensor and electronics. Protons (H+) are released when dNTPs are incorporated on 
the growing DNA strands, changing the pH of the well (ΔpH). The ΔpH is converted in a voltage change (ΔV) 
that is digitized by the off chip electronics. The full digital signs were then processing in a sequencing read. B) 
Here are shown the four chip commercially available and the chip name (Meriman et al, 2012). 
Nowadays, two different Ion Torrent sequencing systems are available, the Ion Personal 
Genome Machine (IPGM) and the Ion Proton sequencer. The two platforms use chips that 
differ each other for the level of throughput. Indeed, for 200bp chemistry, the IPGM chips 
show a capacity ranging from 50Mb of chip 314 to 1Gb of chip 318, allowing the sequencing 
of small target genomic region. Instead, Proton I has an output of 10Gb for exome, 
transcriptome and larger genome sequencing (Figure 1B). The sequencing read length is 
usually of 200bp, even if it is now possible to sequence fragments of 400bp with a good 
accuracy. It has been shown that for a 200bp chemistry the error rate for substitutions is 
~0.1%. However, this percentage increases in the homopolymeric regions, being of 3.5% in 5-
mer homo-polymer (Buermans and Dunnen, 2014). 
Therefore, the Ion Torrent technology is feasible for molecular diagnosis of rare genetically 
heterogeneous diseases characterized by relatively small targets, such as Fanconi anemia (FA) 
and inherited thrombocytopenias (IT), both subject of our research.  
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FANCONI ANEMIA 
Fanconi Anemia (FA) is a rare genetic bone marrow failure disorder with an incidence of 
1/350000 borns. The heterozygote frequency is estimated at 1/350 in Europe and the United 
States, even if founder effects have been demonstrated in different ethnic groups, such as 
Ashkenazi Jews and Afrikaner. In these populations the carrier frequency is of 1/89 and 1/83 
borns, respectively (Tischkowitz and Hodgson, 2003).  
 Clinical features of FA 
FA is characterized by a high phenotypic heterogeneity. Indeed in the first decade of life FA 
patients often, but not always, show a combination of various congenital abnormalities, such 
as short stature; typical facies and microphthalmia; thumb and radius malformations; skin 
hyperpigmentation; neuronal, cardiac, renal and genitourinary malformations. (Tischkowitz 
and Hodgson, 2003). FA phenotype can overlap with that of other diseases, like VACTERL 
syndrome, Thrombocytopenia and Absent Radii syndrome (TAR), Seckel syndrome and 
Diamond-Blackfan syndrome (Auerbach, 2009). Moreover, it is possible that individuals of 
the same family express different phenotype, even if they have the same gene mutations. 
Notably, approximately one-third of FA patients do not manifest major congenital 
malformations. In these patients, FA diagnosis is generally made only after the manifestation 
of hematologic dysfunctions, which generally occurs at a median age of 7 years. FA patients 
have also an increased risk of develop hematological and solid tumors in early age 
(Tischkowitz and Hodgson, 2003). 
 Genetic of FA  
At present, 16 genes (FANC genes) are known to be involved in the disease (FANCA, FANCB, 
FANCC, FANCD1/BRCA2, FANCD2; FANCE; FANCF; FANCG; FANCI; FANCJ/BRIP1, 
FANCL, FANCM, FANCN/PALB2, FANCO/RAD51C, FANCP/SLX4, FANCQ/ERCC4). 
Mutations in these genes are inherited in autosomal manner except for those in FANCB gene, 
which is located on chromosome X. The most frequent genes involved in this pathology are 
FANCA, FANCG and FANCC, which together account for almost 90% of the cases. 
Furthermore, there is a wide spectrum of private mutations, including large intragenic 
deletions that characterized almost 20% of the FANCA alleles (Fanconi Database, The 
Rockfeller University, http://www.rockefeller.edu/fanconi/;  Morgan et al, 1999). 
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 FA pathway 
FANC proteins are involved in a common DNA repair signaling pathway, which closely 
cooperates with other DNA repair proteins for resolving DNA interstrand cross-links during 
replication (Moldovan and D’Andrea, 2009). This pathway is composed of three different 
complexes. Complex I (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL and 
FANCM, also known as the FA core complex) functions as a nuclear E3 ubiquitin ligase. 
During the DNA repair process, the FA core complex, together with the FA associated 
proteins FAAP24 and FAAP100, promotes the monoubiquitination of the FANCD2/FANCI 
heterodimer (complex II). The FANCD2 ubiquitination is indispensable for the DNA repair 
process and the activation of FA pathway. On the contrary FANCI ubiquitination is not 
essential, although it may enhance DNA repair process. Mono-ubiquitinated complex II 
interacts with the third complex, composed by FANCD1/BRCA2, FANCJ/BRIP1, 
FANCN/PALB2, FANCO/RAD51C, FANCP/SLX4, FANCQ/ERCC4 proteins, promoting the 
DNA repair process via homologous recombination (Figure 2) 
 
Figure 2: FA pathway. A schematic diagram showing the three FA complexes and their role in the DNA repair 
process. FA proteins are indicated in green. (Adapted from Soulier, 2011) 
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 FA diagnosis 
The genetic heterogeneity together with the numerous mutations identified in the FA genes 
makes the molecular diagnosis of FA complex and time consuming. As indicated in figure 3, it 
is a tiered process starting from clinical suspicion that is confirmed at the cellular level testing 
sensitivity of patient’s cells to DNA interstrand cross-linking (ICL) agents, such as 
diepoxybutane (DEB test). If the DEB test is positive, identification of mutations is 
fundamental for a correct management of patients in terms of genetic counseling, carrier 
testing, and prenatal diagnosis (Auerbach, 1993). An inconclusive DEB test might occur in 
patients with hematopoietic mosaicism arising from spontaneous genetic events, such as back 
mutations, leading to reversion of the FA cellular phenotype (Waisfisz et al., 1999; Gross, 
2002). Without any knowledge on candidate genes, molecular genetic testing is usually carried 
out starting from FANCA, which is mutated in 60-80% of FA families (Castella, 2011; De 
Rocco, 2014). The analysis consists of Sanger sequencing of 43 coding exons combined with 
MLPA (Multiple Ligation-dependent Probe Amplification). If no FANCA mutation is 
identified, the screening is extended to the other FA genes. Alternatively, the candidate gene 
can be identified by complementation analysis or restricted to the components of the FA 
pathway playing a role up or down of FANCD2 on the basis of its monoubiquitination status 
(Kottemann et al, 2013; Bogliolo et al, 2013). Therefore, FA diagnosis would greatly benefit 
from application of NGS, which could allow to avoid the use of complementation and western 
blot analyses, reducing both time and cost of the process.  
Figure 3: FA diagnosis. A) Schematic 
flowchart of FA diagnosis. B) FA cells are 
hypersensitive to ICL agents that cause 
chromosomal aberrations (red arrows) that are 
detected by the DEB test. C) Western Blot 
analysis reveals FANCD2 monoubiquitination 
defects, indicating in which FA complex 
mutations have occurred. 
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INHERITED THROMBOCYTOPENIA 
Inherited Thrombocytopenias (IT) are an heterogeneous group of different diseases, all 
characterized by a platelet counts lower than 150x109/L. ITs are considered exceedingly rare, 
but their prevalence is unknown because no population-based study has been performed. 
However, a recent work carried-out by the group of Balduini in 2012 has shown that, at least 
in Italy the most frequent disorders are Bernard Soulier Syndrome (BSS) and MYH9-related 
diseases (MYH9-RD). 
 Clinical features 
The most important feature of ITs is increased bleeding tendency, which consists of muco-
cutaneous haemorrhages, nose bleeds, menorrhagia and gastrointestinal bleeding. Patients with 
platelet counts lower than 20-30x109/L suffer from spontaneous often life-threating 
haemorrhages since birth; in most cases the degree of thrombocytopenia is mild and bleeding 
is occasional and related to trauma or surgery. However, some patients, such those affected by 
BSS, show a bleeding tendency disproportionate to the degree of thrombocytopenia because of 
defects associated with platelet function (Balduini et al, 2012). Furthermore, approximately 
half of the ITs are syndromic disorders, associated with additional defects that could affect 
nearly all organs and system. For example patients with Wiskott-Aldrich syndrome (WAS) are 
at risk of infections and those with TAR or Congenital Thrombocytopenia with Radio-Ulnar 
synostosis (CTRUS) have skeletal defects. In other cases, such as in MYH9-RD, affected 
individuals can develop glomerulonephritis, deafness and cataracts during life (Balduini et al, 
2013). 
 Genetic of ITs 
Knowledge about the genetic causes of ITs has greatly improved in the past decade and to date 
22 are the genes involved in these disorders (ABCG5, ABCG8, ACTN1, ANKRD26, CYCS, 
FLI1, FLNA, GATA1, GP1BA, GP1BB, GP9, HOXA11, ITGA2B, ITGB3, MHY9, MPL, 
NBEAL2, RBM8A, RUNX1, TUBB1, VWF, WAS). The pattern of inheritance depends on the 
type of disorders and often is not easy to identify because of de novo mutations. Finally, 
transmission in some disorders, as BSS, may be both  dominant and recessive, causing a more 
or less severe phenotype (Balduini et al, 2012; Balduini and Savoia, 2012; Kunishima et al, 
2013). 
  
11 
 
 Biogenesis of platelets. 
The IT genes encodes for proteins that are involved in the production of platelets from 
megakaryocytes (MK). These are myeloid cells that reside primarily in the bone marrow. In 
early development, the megakaryocitopoiesis occurs within yolk sac and fetal liver and it 
consists of hematopoietic stem cells (HSCs) differentiation and maturation into MKs (Patel et 
al, 2005). The differentiation of MKs in bone marrow is mediated by thrombopoietin (THPO), 
which binds to the c-MPL receptor on the surface of the cell and activates a series of signaling 
pathways. At the end of maturation, MKs result in polyploidy cells with multilobed nucleus 
and DNA content up to 128N. Moreover, during maturation, MKs increase in size, become 
full of platelet specific granules, expand their cytoplasmic content of cytoskeletal proteins and 
develop a highly tortuous invaginated membrane system (IMS), a membrane reservoir for 
platelets’ production. During this phase, MKs migrate from the osteoblastic to the vascular 
niche of the bone marrow, where they start extending proplatelets that protrude into the 
vascular lumen. Finally, platelets are released into the blood stream as preplatelets for their 
conversion in platelets into the vascular vessels (Machlus and Italiano, 2013).  
The complex process of platelets’ biogenesis involves different transcriptional factors, such 
GATA1, RUNX1 and FLI1, and several cytoskeletons’ proteins, such as ACTN1, TUBB1, 
FLNA and MYH9. For most of the IT genes, their functional role remains to be clarified. 
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 ITs diagnosis 
The recognition of genetic origin of ITs is often hampered by several difficulties. First of all, 
the clinical recognition of ITs is often delayed because an overlapping between ITs and 
acquired forms of thrombocytopenia. Thus, to distinguish these forms, it is important to 
carefully analyze the family medical history of probands. Moreover, ITs could be often 
misdiagnosed because of ambiguous platelet count that results both from the combination of 
ethnic-, age- and sex variables and from errors in count measurement by cell counters, 
especially for patients with very large platelets (Balduini et al., 2013).  
Once an IT is diagnosed, to avoid the problem of variable expressivity of clinical features, the 
diagnostic process usually take advantage of the algorithm proposed by the Italian Platelet 
Study Group in 2003 (Figure 4; Balduini et al, 2003). The first step consists of discrimination 
of the syndromic forms from the nonsyndromic ones. The latter are then classified according 
to the platelet size. Finally, to find the potentially candidate gene, molecular tests, such as 
blood film and bone marrow evaluation, ristocetin response analysis and immunofluorescence 
test, are performed. 
Figure 4: Diagnostic algorithm 
for ITs: medical history and 
physical examination are 
sufficient in most cases for 
suspecting syndromic forms. For 
the nonsyndromic forms, further 
investigations of the platelets’ 
size and laboratory tests are 
necessary (Balduini et al, 2013). 
 
 
 
 
Despite of the application of diagnostic algorithm, about the 50% of the IT patients remain 
without a molecular confirm of clinical diagnosis (Balduini et al, 2012). For this reason, ITs 
are a great challenge for the application of the NGS technologies.  
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AIM OF THE STUDY 
Thanks to the development of NGS technologies, such the Ion Torrent platform, is now 
possible to sequence simultaneously more genes and more patients in a single sequencing run. 
This possibility could simplify the diagnostic process of diseases characterized by an high 
genetic and phenotypical heterogeneity. For this reason, we have applied the Ion Torrent 
technology on two different genetically heterogeneous diseases, Fanconi anemia (FA) and 
inherited thrombocytopenias (IT), in order to develop a new diagnostic algorithm for rapid 
molecular diagnosis.  
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MATERIAL AND METHODS 
BIOLOGICAL SAMPLES 
 Fanconi Anemia Samples 
Twenty-eight DNA samples from FA probands with positive DEB test and two from healthy 
controls (14 males and 16 females) were analyzed in this study (Table 1). DNA samples were 
isolated from peripheral blood (n=25) or from lymphoblastoid cell lines (n=5) using a High 
Pure PCR Template Preparation Kit (Roche, Indianapolis, USA). In 25 samples, at least one of 
the most frequently mutated genes (FANCA, FANCC or FANCG) was previously analyzed by 
Sanger sequencing (De Rocco et al, 2014). Of the 28 affected individuals, 15 had both FA 
alleles characterized. In three cases, including two with hematopoietic mosaicism (Waisfisz et 
al, 1999), only one FA allele was identified. In this cohort, 23 FA alleles were still missing. To 
find all potential Copy Number Variants on FANCA gene, all samples were previously tested  
using the Salsa MLPA (multiplex ligation-dependent probe amplification) kit with probe mix 
P031/P032 according to the manufacture protocol (MRC-Holland, Amsterdam, the 
Netherlands). Reactions were run on ABI PRISM 3130 Genetic Analyzer (Applied 
Biosystems, Foster City, USA), and analyzed by Gene Mapper version 3.2 (Applied 
Biosystems, Foster City, USA) and MRC-Holland Coffalyzer software. (MRC-Holland, 
Netherlands) 
 Inherited thrombocytopenia samples 
In this study we have analyzed twenty-one DNA samples (12 males and 9 females) with 
different diagnostic suspicion of Inherited Thrombocytopenia (Table 2). All of these DNA 
samples were isolated from peripheral blood using a High Pure PCR Template Preparation Kit 
(Roche Indianapolis, USA). In 20 samples at least one of the IT genes was previously 
analyzed with Sanger sequencing and all the subjects received a molecular confirm of the 
diagnosis. Only one sample was never screened before.  
All the subjects or their legal guardians gave written informed consent to the investigation, 
according to the Declaration of Helsinki. 
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IPGM SEQUENCING 
The IPGM sequencing was carried out according to manufacturer’s protocols (Life 
Technologies). Briefly, to sequence the coding exons and their flanking regions of the 16 FA 
genes and of the 22 IT genes, we designed two different panel of primers using the Ion 
Ampliseq Designer software (Life Technologies, https://www.ampliseq.com/browse.action). 
Both panel were divided in two pools consisting in 348 and 345 amplicons each FA pools and 
in 327 and 323 amplicons in each IT pools.   
 Libraries preparation 
To construct the libraries we made two multiplex PCR, one for each primer pool, using Ion 
Ampliseq Library kit 2.0 LV, as indicated by manufacturer’s protocols. Then to distinguish 
different sample on the same sequencing chip, each library was partially digest and ligated to 
Ion Xpress Barcode Adapters. 
Libraries were cleaned using Agencourt AMPure XP reagent according to manufacturer 
protocols. Each libraries were then quantified with real-time PCR using Ion Library 
Quantitation Kit in accordance with protocol. Real time PCR was carried out on a 7900 HT 
System 
  Enrichment of libraries (Ion One Touch 2 System)  
To pool together all the libraries in a single sample, we have calculated template dilution 
factor for a final concentration of 10pM per library. Then an enrichment reaction of the 
template was carried out using Ion One Touch 2 system (Ion PGM template OT2 200 kit), 
which consist of two different instruments, the Ion OneTouch Instrument and the Ion 
OneTouch ES. In the first one all the amplicons are bound to the Ion Sphere Particles (ISPs), 
magnetic beads on which the emulsion-PCR reactions takes place. Primers used in this step are 
the same for all the amplicons because complementary to the adapter sequence. The reaction 
products are ISPs presenting millions of copies of a single amplicon on their surface.  
The selection of the template positive ISPs is performed on the Ion OneTouch ES.  
The percentage Template ISPs is determined using the Qubit 2.0 fluorometer. As indicate in 
the manufacturer’s protocol, the optimal amount of library corresponds to the library dilution 
point that gives Percent Templated ISPs between 10–30%. 
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 Ion PGM sequencing 
Libraries combined in a single samples and enriched with Ion One Touch 2 system  were 
sequenced using the Ion PGM sequencer (Ion PGM sequencing 200 kit v.2), according to 
manufacturer’s protocol.  
The number of combined libraries that can be accommodated in a single sequencing run 
depends on the size of the chip, the ability to reliably quantify and combine barcoded libraries, 
and the coverage required. In order to assure high coverage we loaded into 316 chips 12 FA 
libraries (6 DNA samples) or 14 IT libraries (7 DNA samples) into 316 chips. 
 Ion PGM sequencing data analyses 
Sequencing data were analyzed using Ion Torrent Suite software (v 4.0). Using the plug-in 
Coverage Analysis (TSCA v 4.0), we evaluated the quality of data sequencing. Data were 
aligned with hg19 human genomic sequence using the plug-in Variant Caller (TSVC v.4.0). 
Functional annotations of all the sequence variants were performed using the w-annovar 
software (http://wannovar.usc.edu/). Libraries alignment was visualized using Integrative 
Genomics Viewer (IGV) software (Thorvaldsdóttir et ak, 2013).  
Moreover the pathogenic effects of all those variants with MAF<1% was evaluated using four 
pathogenicity prediction programs, such as PoliPhen-2 
(http://genetics.bwh.harvard.edu/pph2/), Mutation Taster (http://www.mutationtaster.org/), 
Mutation Assessor (http://mutationassessor.org/), and SIFT (http://sift.jcvi.org). Since the 
different software use different prediction scales, we converted each output assigning a value 
from 0 to 2. Specifically, we assigned values 0, 1, and 2 to the PolyPhen-2 prediction of 
"benign", "possibly damaging", and "probably damaging", respectively. Values of 0 and 2 
were attributed to "polymorphism" and "disease causing" output of Mutation Taster, 
respectively. To the Mutation Assessor predictions of "neutral", "low", and "medium" we 
assigned values of 0, 1, and 2, respectively. Finally, when the SIFT output was "tolerated" the 
value was 0 and for "not tolerated" was 2. The pathogenicity score was obtained by summing 
the values attributed to the output from the single software. Scores 5 were considered 
pathogenetic. The in silico analyses for detection of potential splicing mutations were carried 
out using Human Splicing Finder Version 2.4.1 (http://www.umd.be/HSF/). 
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 Validation of Ion PGM sequencing data on FA DNA samples 
(Validation I) 
To assess the reliability of Ion PGM sequencing technology, we evaluated the sensitivity 
[TP/(TP + FN)] and the specificity [TN/(TN + FP)], the positive [PPV=TP/(TP+FP)] and the 
negative [NPV=TN/(TN+FN)] predictive values of the technology, comparing Ion PGM 
sequencing data with Sanger data on FANCA, FANCC and FANCG genes at our disposal on 
the 25 FA samples previously analyzed (Table 1).  
 Characterization of novel FA alleles (Validation II) 
All those exons that present variants with MAF<1% were analyzed by Sanger sequencing. 
 Characterization of novel IT alleles 
Among the variants called by TSCV on the 21 IT samples, we selected those with MAF<0.01 
and considered pathogenetic either because present in one of the four public mutation database 
(HGMD, LOVD, OMIM, Clinical Variation), or because having a pathogenicity score ≥5. All 
these variant were validated with Sanger sequencing. 
  Detection of copy number variations in FA samples 
Statistical analyses for detection of copy number variations (CNV) were performed on 
coverage data supplied by TSCA. These analyses implied two normalizations for each sample. 
The first was an intrasample normalization, which was calculated by dividing the total number 
of reads of each amplicon by the total reads average obtained from the same library. Since 
almost 20% of the FANCA alleles are large intragenic deletions (Morgan et al, 1999) and 
FANCB is localized on chromosome X, we excluded the FANCA and FANCB amplicons from 
the calculation of the total reads of each library. The second was an intersample normalization, 
which was determined by dividing the intrasample normalisation of each amplicon by the 
average of all the intrasample normalisation of this amplicon from control samples.  
 As control samples in the intersample normalization of FANCA and FANCB amplicons, we 
used data from 21 samples without FANCA deletions (from MLPA analysis) and from 15 
females, respectively. For the intrasample normalization of amplicons of the other FA genes, 
we use all the samples (n=28) except for P3 and P4, which had the lowest uniformity amplicon 
coverage. All those amplicons that did not achieve the threshold of 30X in more than three 
samples were excluded from the analysis. We considered intersample normalisation ratios 
lower than 0.7 indicative of heterozygous deletions and ratios higher than 1.3 suggestive of 
  
18 
 
duplications. Graphs and statistical analyses were performed using the software Minitab® 
Statistical Software. Median and interquartile range (IQR) were used to described non-normal 
distribution data, whose comparison was performed by the Mann-Whitney test. 
 Detection of copy number variations in IT samples 
Also for IT samples the same statistical analysis based on two normalization steps of coverage 
sequencing data was improved to detect CNV. In this case since WAS, GATA1 and FLNA 
genes are localized on chromosome X and large deletions on RBM8A gene are responsible of 
TAR syndrome (Albers et al, 2012), we excluded the WAS, GATA1, FLNA and RBM8A 
amplicons from the calculation of the total reads of each library in the first normalization step.  
Since 4 samples were excluded from control samples of CNVs because of low uniformity, data 
from 16 samples without RBM8A deletions and from 10 males were used as control samples 
in the intersample normalization of RBM8A and WAS, GATA1 and FLNA amplicons, 17 
samples were used for the intrasample normalization of amplicons of the other IT genes All 
those amplicons that did not achieve the threshold of 30X in more than three samples were 
excluded from the analysis. The same parameters used to indicate the presence of CNVs in FA 
samples were used for IT samples.  
Validation analysis of CNVs was carried out with SNP array, except for FANCA gene, which 
is analyzed with MLPA analysis, and for all those genes localized on chromosome X 
(FANCB, WAS, GATA1 and FLNA). 
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SANGER SEQUENCING 
Bidirectional Sanger sequencing was performed on FA and IT exons carrying variants with 
MAF<1%. PCR reaction was performed using Kapa2G Fast Hot Start mastermix 
(Kapabiosystem)as indicated by manufacturer’s protocol. Quality control of PCR products was 
performed with electrophoresis on agarose gel ( 1% Tris Borate EDTA Buffer). 
Following sequencing steps were performed by IGA technology services (Udine, Italy). 
Sequencing data analysis was done using DNASTAR Lasergene Seqman Software. 
SNP ARRAY 
SNP array analysis was performed using the Human OmniExpress-12 Bead Chip (Illumina 
Inc., San Diego, CA) according to Illumina’s Infinium HD Assay protocol. Normalization of 
raw image intensity data, genotype clustering and individual sample genotype calls were 
performed using Illumina’s GenomeStudio software v2011.1 (CNV partition 3.2.0). The CNV 
calls were determined with generalized genotyping methods implemented in the Penn CNV 
program.  
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RESULTS AND DISCUSSION 
Since FA is a high genetic heterogeneity disease that is better characterized than ITs, we first 
validated the IPGM technology on 2 wild type and 28 FA samples. Of note, among the 56 
mutant alleles, 33 were previously characterized by Sanger sequencing. 
VALIDATION OF ION TORRENT TECHNOLOGY ON 
FA SAMPLES 
 Quality control: high coverage for 95% of amplicons 
The 16 FA genes represent a target of 74.2 kb split into 693 amplicons ranging in size from 
125 to 225bp. The amplicons cover 96% of the coding exon sequences with approximately 
30bp of their flanking intronic sequences. The regions excluded by the design (4%) are 
variably dispersed through all the genes, varying from 0.03% (FANCQ) to 10% (FANCE) of 
the targeted sequences. All samples satisfied the quality control parameters except for P3, 
which was excluded from further analysis because the uniformity of amplicon coverage was 
below 50% (Table 3). 
Coverage analysis found that 35 of the 693 amplicons did not reach the threshold of 30X in at 
least one of the 29 samples (Table 4). Five amplicons were not covered in at least 10 samples, 
suggesting that “constitutive” features of DNA could be responsible for the low sequencing 
efficiency. It is reasonable to hypothesize that repetitive sequences or primer self-annealing 
interfere with amplification rate. For instance amplicon AMPL544050257 (exon 1 of FANCA), 
which is a GC rich region (78%), did not reach the threshold of 30X in 15 samples. For 
amplicons AMPL1197148282 (exon 4 of FANCB), AMPL404630568 and AMPL388340296 
(exons 11 and 20 of FANCD1), and AMPL433543078 (exon 17 of FANCJ), the coverage was 
less than 30X in 12, 10, 21, 15 samples, respectively, more likely because of self-annealing or 
intra-strand loop formation of primers, as revealed by inspection of primer sequences. For the 
remaining 30 amplicons the coverage was less than 30X in 1-7 samples, indicating the 
presence of “occasional” interfering factors (Table 4). The two FANCA amplicons of exon 15 
were not sequenced in P4 because of two large heterozygous deletions encompassing this exon 
(Table 1). In P28, a compound heterozygote for c.523-?_2981+?del and c.548G>A, amplicon 
AMPL544193477 was not covered because it was hemizygous on one allele and not amplified 
from the other for the presence of c.548G>A in one primer complementary sequence. 
Inspection of the other uncovered amplicons did not provide us with any insights into the 
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potential mechanisms of their low coverage. It is likely that allelic drop-out for the presence of 
rare variants occurred. 
 Validation I: high sensitivity and specificity of target NGS 
sequencing  
After sequencing quality evaluation, we determined whether the variants were true (TPs) or 
false positives (FPs) (Figure 5). Of the 2,005 annotations (approximately 70 per sample), we 
selected those (n=173; 48 different) that were located in the genomic regions of FANCA, 
FANCC, and FANCG, the genes we previously screened using Sanger sequencing (208,001nt) 
(De Rocco et al, 2014). Comparing data from the two technologies, we found that all the 173 
variants were TPs because also detected by Sanger sequencing. Among these were 23 known 
mutations of FANCA (Table 1). Of note, no FPs was annotated. In the same regions, however, 
the NGS sequencing did not call 8 variants (false negative - FN; 6 different), one of which was 
the heterozygous c.3761_3762dup mutation of FANCA (P11). This duplication was not called 
because of allelic drop-out as it hit the complementary primer sequences of amplicons 
covering exon 37. Inspection of the other few FNs revealed that they were mainly localized at 
the 5’ and 3’ ends of amplicons, where the coverage drops reducing sequencing reliability. 
Considering these data, it will be useful to carry a careful visual inspection of these low 
covered regions with IGV software to evaluate the presence of potentially pathogenic variants 
that are not called by the TSVC plugin.  
Using these data and considering the number of true negative (TN; N=207,820), we calculated 
the probability that the IPGM sequencing detects mutant or wild type nucleotides. At least for 
the FANCA, FANCC, and FANCG regions included in this validation (validation I; Figure 5), 
sensitivity [TP/(TP + FN)] and specificity [TN/(TN + FP)] are 95.58% and 100%, 
respectively. Considering that the prevalence of the mutant nucleotide is 0.09%, we estimated 
the positive [PPV=TP/(TP+FP)] and the negative [NPV=TN/(TN+FN)] predictive values as 
100% and 99.99%, respectively, indicating that IPGM is a suitable technology for the 
screening of the FA genes. 
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 Validation II: characterization of novel FA alleles  
In addition to 173 TPs (validation I), the analysis called another 1,832 variants (Figure 5), 
some of which were expected to be the mutations (23 alleles) not characterized yet in our 
cohort (Table 1). The MAF<0.01 filter allowed us to select 171 putative pathogenetic variants. 
Screening the relative genomic regions by Sanger sequencing (36,299nt; validation II; Figure 
5), we could validate another 36 annotations that were previously excluded because of their 
MAF>0.01. Of these 207 variants, 83 (67 different) were TPs and 124 (19 different) FPs. No 
FN variant was missed. 
Among the 67 different TPs, we searched for known FA mutations and/or deleterious variants, 
such as nonsense and frameshift mutations, putative alternative splicing variants and amino 
acid substitutions with high pathogenetic prediction score (see Materials and Methods). This 
allowed us to characterize 15 mutant alleles of FANCA, FANCC, FANCF and FANCL in eight 
(P21-P24, P26, P27, P29 and P30) of the ten samples without any FA mutations (Table 1). In 
particular, in sample P30 we identified three different missense mutations in FANCL, whose 
pathogenetic effect has been demonstrated by complementation analysis (De Rocco and 
Hanneberg, unpublished data). Of interest, one pathogenetic variant of FANCL (p.Pro17Arg) 
was also detected on one allele of control sample W2 (Table 1). The remaining TPs were 
heterozygous variants, most of which reported as SNPs in databases. They mainly hit intronic 
regions outside the consensus splice site sequences, though five could create cryptic splice 
sites (Table 5). Further analyses on patients’ RNA samples should be performed to confirm 
their pathogenetic effect. 
 Others TPs were synonymous or benign missense variants, as determined by bioinformatics 
tools. However, nine, all in genes other than those causing the disease, were predicted to be 
pathogenetic: seven missense mutations of FANCD1, FANCD2, FANCJ, FANCM, and 
FANCN, one frameshift (p.Thr367Asnfs*13) one nonsense (p.Glu417*) mutations of FANCL 
and FANCM, respectively (Table 1, Table 5). 
Of the 19 different FPs, four were called in more than 22 patients, suggesting that they could 
be filtered in a standardized diagnostic workflow (Table 6). As expected, FPs were mainly 
localized in homopolymeric regions (Bragg et al, 2013). 
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Figure 5: Schematic representation of the study on FA samples. The IPGM sequencing output underwent a quality control 
process leading to exclude P3 from all the further analyses and P4 from the CNV detection. Among the 2,005 variants called 
by IPGM, 173 were selected for validation I, as they were localized in regions (208,001nt) that were previously analyzed by 
Sanger sequencing in at least one of the most frequent FA gene (FANCA, FANCC and FANCG). Results of validation I were 
used to calculate sensitivity and specificity (95,58% and 100%, respectively). In validation II, variants with MAF<0.01 
(N=171) were filtered from of the 1,832 variants in regions analyzed exclusively by IPGM for Sanger sequencing, analysis 
that included another 36 variants with MAF>0.01. The number of TP (true positive), FP (false positive), FN (false negative), 
and TN (true positive) variants from validations I and II are also indicated. Of the 83 TP, 15 (two on the same FANCL allele) 
were pathogenetic variants. Amplicon coverage data were also analyzed to detect CNVs (N=7) 
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 Identification of FA copy number variations:  
correct assignment of gender  
To determine whether the IPGM data were suitable for copy number variation (CNVs) 
detection, we analyzed FANCB, the only FA gene located on chromosome X. Consistent with 
our knowledge on gender, all males had median and IQR below 0.7, which is indicative of 
hemizygosity (Figure 6). In females, whereas the median always ranged between 0.7 and 1.3, 
the box plots was just above the threshold of 1.3 in three cases (P17, P22, and P23). In P4, the 
attribution of gender was instead ambiguous as the IQR ranged from 0.27 to 1.31 (Figure 6). 
Although we cannot exclude a partial deletion of FANCB, P4 was excluded from the CNV 
analysis also considering its relatively low uniformity index (86.9%; Table 3). The differences 
observed between males and females were not due to random variations of the FANCB 
coverage in almost all cases, as indicated by the Mann-Whitney tests’ results (Table 7). 
 
Figure 6: CNV analysis of the FANCB amplicons. The values were represented by medians of intersample 
normalization ratio and box plots reporting the interquartile range (IQR). A median below 0.7 or between 0.7 and 
1.3 is indicative of a single or double copy of the gene. In the FANCB box plot, the median is always below 0.7 
and between 0.7 and 1.3 in all the males (blue) and females (pink) respectively. 
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 Identification of FA copy number variations: deletions of the entire 
FANCA and FANCD2 genes  
After gender attribution, we determined whether other FA genes were affected by CNVs. 
Using the same criteria as above, we found that the median and IQR of the intersample 
normalization ratios in FANCA and FANCD2 was significant lower than expected in samples 
P15 and P9, respectively (Figure 7A and 7B). The hemizygous condition of the two genes was 
confirmed by MLPA and SNP array, respectively (Figure 7A and 7B). Of note, since P9 was a 
compound heterozygous with two mutant alleles of FANCA (Table 1), it would be interesting 
to explore whether loss-of-function of FANCA together with haploinsufficiency of FANCD2 
makes the phenotype worse. 
 
Figure 7: Detection of large deletion of the entire FANCA and FANCD2 genes. A) In the FANCA box plot 
(figure 7A.1) the median of amplicon coverage is lower than 0.7 in the sample P15 (blue arrow), suggesting the 
presence of a deletion of the entire FANCA gene. This data was confirmed by MLPA analysis (figure 7A.2). B) 
The median of amplicon coverage of FANCD2 is in the normal range for all the samples except for P9 (green 
arrow, figure 7B.1). This data is indicative of a large deletion of the entire FANCD2, which is confirmed by SNP 
array. In figure 7B.2, the plot for the B allele frequency shows a heterozygous deletion of 11.6 Mb (235,748-
11,880,816) on chromosome 3p26.3-p25.2 containing the FANCD2 gene. In this patient the plot has 10% 
heterozygous (AB) SNP calls, as shown by the additional allele frequency, indicating a mosaicism of 
approximately 90%. For probes that are normal copy number, the signal intensity ratio of the subject versus 
controls is expected to be 1, and log2 R ratio should be approximately 0.0 (log21 = 0). In the other plot loss of 
copy number results in a negative log2 ratio of approximately −0.5. 
  
26 
 
 Identification of FA copy number variations: characterization of 
large intragenic deletions of FANCA 
In trying to detect partial CNVs of FANCA, we first used the IGV software and found that in 
samples with known intragenic deletions the coverage of the deleted exons was reduced 
respect to that of the flanking undeleted amplicons. Then, a statistical evaluation revealed that 
the first quartile of the coverage distribution were below the threshold of 0.7 in P16 
(IQR=0.67-1.0), P23 (IQR=0.58-0.95), P27 (IQR=0.66-1.09), and P28 (IQR=0.48-1.01) 
(Figure 8).  
 
Figure 8:Large intragenic deletions in FANCA gene. In patient P16, P27 and P28 (blue arrows) the 1st quartile of the 
coverage distribution was below 0.7 (P16 =0.67, P27=0.66 and P28=0.48) suggesting potential intragenic deletions of 
FANCA. This data were confirmed with MLPA analysis. Also in P23 (red arrow) the 1st quartile of the coverage distribution 
was below 0.7, being of 0.58, but MLPA analysis didn’t show any CNVs in this patient. The asterisks indicate the outliers. 
Considering that smaller the deletion more the intersample normalization ratios of amplicons 
coverage resides within the normal range, we plotted the intersample normalization ratio of 
each amplicon. In P16, P17, P18, and P19 we confirmed the deletions we previously detected 
by MLPA (Table 1) (De Rocco et al, 2014). In P27 and P28 we identified two novel deletions 
encompassing exons 21-29 and exons 6-30, respectively, which were confirmed by MLPA 
analysis (Figure 9). Despite its first quartile was below 0.7, amplicon plots and MLPA analysis 
did not reveal any CNV in P23. 
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Figure 9: Detection of large intragenic deletions in FANCA. IPGM and MLPA analysis of two novel deletions of exons 
21-29 (P27) and exons 6-30 (P28). Amplicons from the two IPGM libraries (IPGML1 and IPGML2) are reported in graphs 
showing hemizygous amplicons in red. MLPA output of two probes mix (MLPAP031 and MLPAP032) from the 
Coffalayzer.net software, showing FANCA exons and reference loci (R) values. In both IPGM and MLPA analysis, the 
intersample normalization of deleted adjacent exons is under the threshold of 0.7 (red line) 
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DEVELOPMENT OF A NEW DIAGNOSTIC PROCESS 
FOR THE STUDY OF DISEASES WITH HIGH GENETIC 
HETEROGENEITY 
After exclusion of two samples whose sequencing quality was not satisfactory, the IPGM 
technology allowed us to identify 44 of the 52 mutant alleles, including large intragenic 
deletions of FANCA, expected in our cohort of 26 FA DNA samples. In 19, both mutant alleles 
were characterized including those in relatively rare – at least in our population – 
complementation groups, such as FANCC, FANCF, and FANCL. In six cases (P11, P13, P19, 
P20, P28 and P29), only one heterozygous mutation was detected whereas no variant was 
found in P25. Whereas the second allele in P11 and P28 were FNs, the other six missed alleles 
could lie within uncovered amplicons. Thus, Sanger sequencing of these regions identified the 
second mutant FANCA allele in patient P29 (c.50dup), that is located in exon 1 of FANCA, the 
only amplicon not covered in the gene (Table 4). In the remaining patients, one (P13, P19, and 
P20) or two (P25) pathogenetic alleles remained uncharacterized. Considering that P13 and 
P19 were referred as potential hematopoietic mosaics and that a mosaic condition could not be 
excluded in P20, back mutations could have interfered with the detection of the second 
mutation if present only in a small percentage of reads. Finally, since in P25 we did not find 
any mutation, it is likely that a novel FA gene is responsible for the disease in this patient. 
Taken together these data indicate that IPGM is a feasible platform for identifying mutations 
in the FA genes. For this reason, we have developed a diagnostic process for rapid and 
efficient molecular diagnosis (Figure 10). Briefly, without any previous complementation or 
protein analyses positive DEB test samples are analyzed with IPGM technology. After a 
quality control of sequencing, both CNVs and point mutations are searched. Detection of 
CNVs is based on normalization analyses. Results ranging from 0.7 and 1.3 are indicative of 
normal data, those out from this range are suggestive of presence of CNVs, which are 
eventually confirmed or with MLPA or with SNP array. For identification of point mutations, 
we consider the variant caller list, in which all the variants with MAF<0.01 will be selected for 
further filtering. The variants enlisted in FA database or predicted to be pathogenetic will be 
confirmed by Sanger sequencing. Targeting all the FA genes, we cannot exclude identification 
of mutations in more than one gene. However, the recessive model of inheritance or 
complementation analysis will help defining correctly the gene responsible for the disease. 
Applying this algorithm to our FA patient cohort, we would have confirmed only 47 (1.2 per 
sample) variants by Sanger sequencing. Of these, 38 hit the disease-causing genes and 9 were 
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potential mutant alleles in the other FA genes, suggesting that this flow-chart is useful to 
further reduce time and costs of the analyses.  
 
 
Figure 10: Proposal for a diagnostic algorithm using NGS in FA. Flow-chart showing the different steps for IPGM data 
processing. Samples with high uniformity of amplicon coverage are analyzed to detect CNVs and point mutations. CNV 
detection implies two amplicon coverage normalizations and CNV quality control consisting of correct gender assignment 
based on hemizygosity FANCB in males. Normalization ratios of other FA genes allow identification of potential CNVs 
(ratios <0.7 and >1.3 are indicative of deletions and duplications, respectively) that can then be confirmed by MLPA or SNP 
arrays. Simultaneously, variants from the Variant Caller list are filtered out if MAF>0.01 or if included in the FA false 
positive (FP) database. Mutations enlisted in FA database or resulting pathogenetic using prediction tools are selected for 
Sanger sequencing. The recessive model of inheritance will help defining correctly the gene responsible for the disease. 
In conclusion the new diagnostic algorithm proposed for FA in this study combines the 
detection of CNVs with the identification of point mutations in all the FA genes. This allows 
us to provide rapidly patients and their families with molecular diagnosis, which is crucial for 
a correct management of patients in terms of genetic counseling, carrier testing and prenatal 
diagnosis. Therefore, we hypothesized that the application of this new diagnostic algorithm 
could be also extend to the study of other diseases with high genetic heterogeneity, as 
inherited thrombocytopenias (IT), which are another field of interest of our laboratory. 
  
30 
 
APPLICATION OF THE NOVEL DIAGNOSTIC 
PROCESS TO THE DIAGNOSIS OF INERITHED 
THROMBOCYTOPENIA 
To verify whether the IPGM technology could be applied for molecular diagnosis of ITs, we 
analyzed 21 patients with different forms of IT. In all, mutations (27 mutant alleles) were 
previously identified according to the diagnostic algorithm for ITs (Balduini et al, 2003). 
 First step: quality control. 
The coding exons of the 22 IT genes and approximately 30bp of the intronic flanking regions, 
as well as the 5’ UTR regions of the RBM8A and ANKRD26 genes, results in 122.85kb in size 
separated into 650 amplicons, which cover the 95% of the target. The remaining 5% consists 
of regions variably dispersed through all the genes varying from 0.07% (FLNA) to 29.93% 
(RBM8A). In particular RBM8A and ANKRD26 are the lowest covered genes (coverage of 
70.07% and 76.62% respectively) because of the presence of repetitive sequences in the 
3’UTR.  
The sequencing quality was lower than that reached for FA samples (Tables 3 and 8). In 
particular, the percentage of amplicon coverage uniformity (87.2%±5.8), as well as the 
percentage of reads on target (77.9%±8.8), was lower in IT than in FA samples. DNA sample 
quality, presence of highly repetitive regions and pseudogenes (ANKRD26 and TUBB1) are 
likely to have interfered with sequencing efficiency. Despite this, we carried out the CNV 
study as the coverage uniformity was homogeneous among all IT samples, except for the IT8 
(72.97%), IT10 (82.57%), IT16 (83.8%) and IT18 (72.48%) samples that were excluded from 
CNVs control samples. 
The low efficiency of IT primer panel is confirmed also by the coverage analysis: 56 of the 
650 amplicons did not achieve the threshold of 30X (Table 9). In particular, 27 were not 
covered in at least 10 samples, indicating that “constitutive” features of DNA, such as primer 
self-annealing and intra-strand loop formation or presence of GC rich regions (77%) and 
repetitive sequences, could have interfered with amplification reactions (Table 9).  
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 Second step: characterization of novel IT alleles. 
After sequencing quality control, we analyzed the 2,225 variants identified in the 21 IT 
samples (on average 105 variants per sample). Among these, we selected the variants (N=116; 
70 different) with MAF<0.01 (Figure 11, Table 10). Since there is no a comprehensive IT 
mutational database, we took into consideration the LOVD, HGMD, ClinVar, and OMIM 
databases, where 14 (13 different) potentially pathogenic variants resulted to be enlisted 
(Figure 13, Table 10).  
The remaining 102 (57 different) variants were divided into these categories: 
 22 synonym (12 different); 
 35 missense (19 different); 
 1 frameshift; 
 1 nonsense; 
 43 intronic (24 different); 
In order to recognize the remaining pathogenic alleles, first of all we looked at deleterious 
alterations, such as the nonsense mutation c.2187C>A p.(Tyr729*) in NBEAL2 or the 
frameshift deletion c.2613del p.(Leu872Cysfs*38) in ITGA2B. Then, we evaluated the 
pathogenicity of missense and intronic variants with the same software used for FA analysis 
and identified 61 (27 different) variants with a high pathogenetic prediction score. These 
mutation together with those enlisted in the IT mutation database variants (N=75; 40 different) 
were validated by Sanger sequencing (Figure 11, Table 10 indicated by red arrow). Of these, 
30 (27 different) were confirmed: 16 mutations and 14 in genes other than those causing the 
disease. (Figure 11, Table 10 in blue). As described for FA, we found FPs (N=45; 13 different) 
mainly located into homopolymeric regions that were included into a FP database we have 
been generating for ITs to be used as an additional filter.  
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Figure 11: Application of the IT 
diagnostic algorithm to search 
point mutations. Of the 2,225 
variants called by the Variant Caller 
in 21 IT patients, 75 were 
potentially pathogenic on the basis 
of MAF, presence in mutation 
databases and pathogenicity. Of 
these variants, 30 (16 IT mutant 
alleles and 14 in genes different than 
those causing the disease) were 
confirmed by Sanger sequencing. 
The remaining 45 FP variants were 
used to create a FP database to be 
used as an additional filter. 
 
 
 
 
 
 
 
Six known mutant alleles were not called by IPGM. An accurate visual inspection of IGV 
alignment revealed that the homozygous c.392A>C mutation of GP1BB was not covered by 
primer design, whereas the heterozygous c.967+5_2del variant of RUNX1 was located within 
the complementary primer sequence of exon 7. Another heterozygous mutation (c.287C>T) of 
MYH9 is instead localized in a region with low sequencing reliability, being at the 3’end of 
AMPL1254778695. Finally, the homozygous c.382G>T nucleotide substitution in MPL is 
localized in AMPL41082843, an amplicon that was covered less than 30X in more than 3 
patients (Table 10). Since the remaining 2 alleles are large intragenic deletions of RBM8A in 
IT18 and IT19 patients (Table 2), the CNV analysis could allow us to detect them. 
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 Third step: CNVs analysis 
a. Identification of  IT CNVs: Correct Assignment of Gender 
In order to detect CNVs in IT samples, we first determined the correct assignment of gender, 
analyzing WAS, GATA1 and FLNA, the three IT genes localized on chromosome X. As 
indicate in figure 13, the gender attribution was correct in all patients. Indeed, the 
hemizygosity condition of these genes is indicated by median values below 0.7 in males and 
values ranging from 0.7 to 1.3 in females. The only exception is IT16, whose median value is 
above the threshold for FLNA. As for FA, we performed the Mann-Whitney test to confirm 
that the differences observed between males and females were not due to random variations of 
the FLNA, WAS and GATA1 coverage in almost all cases (Table 11) 
Figure 13: CNV analysis of the 
FLNA, GATA1 and WAS 
amplicons. Values are represented by 
medians of intersample normalization 
ratio and box plots reporting the 
interquartile range (IQR). A median 
below 0.7 or between 0.7 and 1.3 is 
indicative of a single or double copy 
of the gene. In the FLNA, GATA1 and 
WAS the median is always below 0.7 
and between 0.7 and 1.3 in all the 
males (blue) and females (pink), 
respectively, except for the FLNA 
amplicons which are above the 
threshold in samples IT16. 
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b. Identification of IT Copy Number Variations: Deletions of RBM8A 
TAR patients are compound heterozygotes carrying one null allele (mainly microdeletions on 
chromosome 1q21.1) and one of the two low-frequency noncoding SNPs (rs139428292 and 
rs201779890) in the 5’UTR region or intron 1 of RBM8A on the other allele (Albers et al, 
2012). Since the two TAR individuals (IT18 and IT19) included in this study were apparently 
homozygous for the c.-21G>A SNP (rs139428292), we used the IPGM output data to confirm 
the hemizygous condition of RBM8A. In both cases, the median and the IQR values were 
below the threshold of 0.7 (Fig. 14). 
 
Figure 14: CNV analysis of RBM8A gene. In the RBM8A box plot, the median of coverage amplicons is below 
0.7 in TAR patients IT18 and IT19, confirming the hemizygous condition of RBM8A likely due to a large 
deletion on chromosome 1q12. 
 
. 
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c. Identification of Copy Number Variations in the other IT genes. 
The statistical analysis implemented to detect CNVs did not show any structural variants in the 
other IT genes, except for ANKRD26, which resulted to be duplicated in IT5 and IT8 and 
deleted in IT10, IT16, IT18 (Figure 15). As indicated in the database of Genomic Structural 
Variations (dbVar, http://www.ncbi.nlm.nih.gov/dbvar), several CNVs have been reported 
within the chromosomic region containing ANKRD26. Some are also associated with diseases 
other than ITs. However, since their pathogenic effect is not clear, they should be first 
confirmed by complementary techniques, such as SNP array, and then considered in 
genotype/phenotype correlation studies to understand whether the ANKRD26 CNVs make the 
patients’ phenotype worse.  
 
 
Figure 15: CNVs analysis of ANKRD26 gene in the IT samples analyzed in this study. Box plots report 
median, IQR and outliers (asterisks). For all the samples, median and IQR range between 0.7 and 1.3 except for 
IT5 and IT8, in which a median above 1.3 is indicative of duplications, and for IT10, IT16 an IT18, in which a 
median lower than 0.7 is indicative of deletions.. 
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CONCLUSIONS 
In this work, we tested whether the IPGM sequencing technology could be applied to the study 
of diseases with high genetic heterogeneity. First of all, we validated the technology on 28 FA 
patients and 2 wild type samples. After exclusion of 2 samples due to low sequencing quality, 
we found that at least for FANCA, FANCC and FANCG genes, the sensitivity and the 
specificity were high, being of 95.58% and 100%, respectively. Moreover, we identified 
mutations, including large deletions of FANCA, in 25 of the 26 FA patients. Since we cannot 
exclude that new genes are involved in the disease, the only patient without any mutation 
identified is suitable for whole exome analysis.  
Taking advantage from these data we have developed a diagnostic algorithm, that combine the 
study of point mutations with the CNVs analysis. In order to evaluate if this diagnostic process 
is feasible also for the study of the other genetically heterogeneous diseases, we have applied 
it also to ITs. 
 Despite the lower efficiency of IT primer panel, sequencing 21 IT samples we identified 
2,225 variants. Of these, those (N=75) enlisted in the IT mutational databases or predicted to 
be pathogenic were confirmed by Sanger sequencing. Mutations, including deletions of 
RBM8A in TAR, were characterized in 17 patients.. The mutations missed in the remaining 4 
patients were located or in regions with low or no coverage, as c.392A>C in GP1BB. To 
increase the mutational detection rate in IT, we will design a second panel of primers for 
amplification of uncovered regions, as well as of the coding regions of genes (ETV6, GFI1B, 
and PRAKCG) that have recently been cloned (Zhang, 2015; Stevenson et al, 2014; Manchev 
et al, 2014). As in FA, potential heterozygous pathogenic mutations were identified in loci 
different than the disease-causing gene. Since FA is a recessive disease, mutations in more 
than one gene could affect potential genotype/phenotype correlation but not the correct 
attribution of the complementation group. On the contrary, ITs are mainly dominant diseases. 
Identification of variants in more than one gene would prevent us from identifying the 
molecular basis of the thrombocytopenia unless genetic and functional studies are carried out.  
Therefore, we regard the diagnostic protocol we have developed as a useful tool for the routine 
molecular diagnosis of FA and ITs. It allows us to achieve a rapid and reliable search without 
any previous investigations, such complementation and/or protein analyses in FA and a series 
of molecular analyses in IT (Balduini, 2003), aimed at identifying candidate genes for 
mutational screening. 
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TABLES 
TABLE 1:FEATURES OF FA DNA SAMPLES INCLUDED IN THE STUDY. 
DNA 
sample ID Gender 
DNA 
sample 
source
┼
 
FANC genes 
analyzed by Sanger 
sequencing 
Mutant gene Mutations identified by Sanger 
sequencing ╪ 
Mutations identified by Ion 
PGMTM ╪ Reference 
W1 M PBC A, G Wild type none None This study 
W2 F PBC A, C, G Wild type none c.50C>G, p.(Pro17Arg) in 
FANCL This study 
P3 M PBC A FANCA 
c.3558dup, p.(Arg1187Glufs*28) 
Excluded from all analyses De Rocco et al, 2014 (FA29) c.1360-?_2778+?del 
p.(Ala454_His926del) 
(del ex15_28) 
P4 F PBC A FANCA 
c.1360-?_1470+?del 
p.(Ala454_Gln490del) 
(del ex15) Excluded from CNV analysis De Rocco et al, 2014 (FA40) c.894-?_3348+?del 
p.(Trp298*) 
(del ex11_33) 
P5 M PBC A FANCA c.3788_3790del, p.(Phe1263del) Confirmed De Rocco et al, 2014 (FA1) c.3788_3790del, p.(Phe1263del) 
P6 F PBC A FANCA c.3239G>A, p.(Arg1080Gln) Confirmed De Rocco et al, 2014 (FA10) c.3971C>T, p.(Pro1324Leu) 
P7 M PBC A FANCA 
c.457C>T, p.(Gln153*) Confirmed 
c.1466T>C, p.(Ile489Thr) in 
FANCJ and c.1249G>T, 
p.(Glu417*) in FANCM 
De Rocco et al, 
2014 (FA13) 
c.709+1G>A 
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P8 M PBC A FANCA 
c.3788_3790del, p.(Phe1263del) Confirmed 
c.1096_1099dup, 
p.(Thr367Asnfs*13) in FANCL 
De Rocco et al, 
2014 (FA21) c.3971C>T, p.(Pro1324Leu) 
P9 F PBC A FANCA 
c.2638C>T, p.(Arg880*) Confirmed 
c.-78-?_5024+?del  
(del ex1_44) in FANCD2 
De Rocco et al, 
2014 (FA37) c.3164G>A, p.(Arg1055Gln) 
P10 F LCL A FANCA c.3638_3639del, p.(Pro1213Argfs*64) Confirmed De Rocco et al, 2014 (FA42) c.3971C>T, p.(Pro1324Leu) 
P11 F LCL A FANCA 
c.3761_3762dup, 
p.(Glu1255Argfs*12) False negative
#
 
De Rocco et al, 
2014 (FA43) 
c.2574C>G, p.(Ser858Arg) 
Confirmed 
c.2204G>A, p.(Arg735Gln) in 
FANCD2 
P12 M PBC A FANCA c.2290C>T, p.(Arg764Trp) Confirmed De Rocco et al, 2014 (FA44) c.4029T>G, p.(His1343Gln) 
P13§ M PBC A FANCA 
c.1450G>C, p.(Glu484Gln) Confirmed 
This study 
not found not found 
P14 M PBC A, G FANCA c.1115_1118del, p.(Val372Alafs*42) Confirmed De Rocco et al, 2014 (FA85) c.1126C>T, p.(Gln376*) 
P15 M PBC A FANCA 
c.2812_2830dup, p.(Asp944Glyfs*5) 
Confirmed De Rocco et al, 2014 (FA20) c.-42-?_5481+?del (del ex1_43) 
P16 M PBC A FANCA 
c.1850_1859del, p.(Leu617Profs*20) 
Confirmed De Rocco et al, 2014 (FA67) c.1827-?_2778+?del 
p.(Arg609Serfs*2) 
(del ex21_28) 
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P17 F PBC A FANCA 
c.457C>G, p.(Gln153Glu) 
Confirmed 
 c.1538G>A, p.(Arg513Gln) in 
FANCG and  
c.2816T>G, p.(Leu939Trp) in 
FANCN 
De Rocco et al, 
2014 (FA65) 
c.3490C>T, p.(Pro1164Ser) 
c.1471-?_1626+?del 
p.(Val491_Glu542del) 
(del ex16_17) 
P18 F PBC A, C, G FANCA 
c.893+5G>A 
p.(Phe879Valfs*19) Confirmed 
c.1151C>T, p.(Ser384Phe) in 
FANCD1 
De Rocco et al, 
2014 (FA28) c.190-?_283+?del 
p.(Val64Alafs*43) 
(del ex3) 
P19ǁ F PBC A, G FANCA 
c.1360-?_1826+?del 
p.(Ala454Serfs*3) 
(del ex15_20) 
Confirmed De Rocco et al, 
2014 (FA61) 
not found not found 
P20¶ M PBC A, C, G FANCA 
c.4258G>T, p.(Glu1420*) 
Confirmed 
c.874C>G, p.(Pro292Ala) and 
c.5848T>G, p.(Leu1950Val) in 
FANCM 
De Rocco et al, 
2014 (FA41) 
not found not found 
P21 F PBC A, G FANCC not found c.67del, p.(Asp23Ilefs*23) De Rocco et al, 2014 (FA88) c.67del, p.(Asp23Ilefs*23) 
P22 F LCL A, G FANCC not found c.37C>T, p.(Gln13*) De Rocco et al, 2014 (FA89) c.692_694del, p.(Lys231del) 
P23 F PBC A, G FANCC not found 
c.37C>T, p.(Gln13*) 
This study c.1069C>T, p.(Gln357*) c.9875C>T, p.(Pro3292Leu) in 
FANCD1 
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P24 F LCL G FANCF not found 
c.484_485del 
p.(Leu162Aspfs*103) 
This study c.484_485del p.(Leu162Aspfs*103) 
c.1538G>A, p.(Arg513Gln) in 
FANCG 
P25 M PBC A, G not found not found not found This study 
P26 M PBC none FANCA not analyzed 
c.3788_3790del, p.(Phe1263del) 
De Rocco et al, 
2014 (FA58) 
c.826+3del, 
p.(250_251insGlyAlaPhe 
MetThrArgCysGlyPheLeu) 
P27 F PBC none FANCA not analyzed 
c.1776+7A>G, p.(Ile573Serfs*12) 
De Rocco et al, 
2014 (FA66) 
c.1827-?_2852+?del, 
p.(Ala610_Arg951del) 
(del ex21_29) 
P28 F PBC none FANCA not analyzed 
c.548G>A, p.(Trp183*)^ 
De Rocco et al, 
2014 (FA49) 
c.523-?_2981+?del 
p.(Ser175Leufs*5) 
(del ex6_30) 
P29 F PBC none FANCA not analyzed 
c.3660del, p.(Asn1221Thrfs*26) De Rocco et al, 
2014 (FA47) c.50dup, p.(Arg18Profs*19)┼┼ 
P30 M LCL none FANCL not analyzed 
c.50C>G, p.(Pro17Arg) 
This study c.676C>T, p.(Arg226Cys) 
c.1021T>A, p.(Trp341Arg) 
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┼PBC, peripheral blood cells; LCL, lymphoblast cell line. 
╪
 Nucleotide A of the ATG translation initiation start site of the FANCA, FANCC, FANCD1, FANCD2, FANCF, FANCG, FANCJ, FANCL, FANCM and FANCN cDNAs from 
GenBank sequences NM_000135.2, NM_000136.2, NM_000059.3, NM_001018115.1, NM_022725.3, NM_004629.1, NM_032043.2, NM_018062.3, NM_020937.2 and 
NM_024675.3, respectively is indicated as nucleotide +1. In square brackets are potential pathogenetic heterozygous variants identified in genes different from that causing the 
disease. 
§Sib of patient FA70 in De Rocco et al. (2014). As FA 70, who was found to be a, P19 was enrolled as an FA patient with a potential hematopoietic mosaicism. For this reason, the 
second mutant allele could be missed. 
ۅPatient with potential hematopoietic mosaicism because of revertant lymphoblastoid cell line. Complementation analysis carried out in peripheral blood T lymphocytes assigned this 
patient to FANCA genetic group but only one heterozygous mutation was identified. Due to the mosaic suspicion, the second mutant allele could be missed. 
¶Potential hematopoietic mosaicism status was not ascertained in this patient, whose peripheral blood cells were the only biological sample available. 
#Mutation localized in a region where the reverse and forward primers of two adjacent amplicons aligned, reducing sequence efficiency of this mutant allele. Mutation was not called 
by the TSVC because seen only 47 of 262 reads. 
┼┼Identified by Sanger sequencing of AMPL544050257 (exon 1), the only amplicon uncovered in FANCA. 
^Variant not identified because of allelic dropout in exon 15 of FANCA. 
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TABLE 2: FEATURES OF IT DNA SAMPLES INCLUDED IN THE STUDY. 
DNA 
sample ID Gender 
DNA 
sample 
source┼ 
IT genes analyzed 
by Sanger 
sequencing 
Mutant gene Mutations identified by Sanger 
sequencing ╪ 
Mutations identified 
by Ion PGMTM ╪ Reference 
IT1 M PBC ACTN1 ACTN1 c.751G>A, p.(Gly251Arg) Confirmed Bottega et al., 2014 
IT2 M PBC ACTN1 ACTN1 c.2210C>A, p.(Thr737Asn) Confirmed Bottega et al., 2014 
IT3 F PBC ANKRD26 ANKRD26 c.-127A>T, p.(=) Confirmed Pippucci et al., 2011 
IT4 F PBC ANKRD26 ANKRD26 c.-134G>A, p.(=) 
Confirmed [c.1212-7T>A in 
ABCG8 and c.2473+53C>A in 
NBEAL2] 
Pippucci et al., 
2011 
IT5 M PBC C-MPL C-MPL 
c.3239G>A, p.(Arg1080Gln) Confirmed [CNV in ANKRD26; 
c.5143G>A in MYH9 and 
c.270+95delT in RUNX1] 
This study 
c.3971C>T, p.(Pro1324Leu) 
IT6 F PBC C-MPL C-MPL c.382G>T, p.(Asp128Tyr) False Negative§ Savoia et al., 2007 
IT7 M PBC CYCS, ANKRD26 CYCS c.154G>A, p.(Ala52Thr) Confirmed This study 
IT8 M PBC GATA1 GATA1 c.647G>A, p.(Arg216Gln) 
Confirmed [CNV in ANKRD26; 
c.220+71G>A and c.7548+66C>G 
in WVF] 
Excluded from CNVs control 
samples†† 
This study 
IT9 M PBC GP1BA GP1BA c.104del, p.(Lys35Argfs*4) Confirmed [c.67+32C>A in 
RBM8A] This study 
  
  
43 
 
IT10 M PBC 
GP1BA,  
GP1BB, 
GPIX 
GP1BB c.47T>C, p.(Leu16Pro) 
Confirmed [CNV in ANKRD26 
and c.2473+53C>A in NBEAL2] 
Excluded from CNVs control 
samples†† 
This study 
IT11 F PBC GP1BA, GP1BB, GPIX GP1BB c.392A>C, p.(Tyr131Ser) False negative
ۅ
 This study 
IT12 F PBC ITGB3 ITGB3 c.2134+1G>C Confirmed [c.1898+33C>T  in NBEAL2] This study 
IT13 F PBC MYH9 MYH9 c.287C>T,  p.(Ser96Leu) False negative¶ This study 
IT14 M PBC MYH9 MYH9 c.2114G>A,  p.(Arg705His) 
Confirmed [c.1385+89A>C  
in ACTN1 and  
c.5026A>G, p.(Lys1676Glu)  
in MYH9] 
Verver et al, 
2014 
IT15 F PBC MYH9 MYH9 c.2114G>A, p.(Arg705His) Confirmed Verver et al, 2014 
IT16 F PBC MYH9 MYH9 c.5521G>A, p.(Glu1841Lys) 
Confirmed [CNV in ANKRD26] 
Excluded from CNVs control 
samples†† 
This study 
IT17 M PBC ANKRD26, NBEAL2 NBEAL2 c.2187C>A, p.(Tyr729*) Confirmed 
Bottega et al, 
2013 
IT18 M PBC RBM8A RBM8A 
deletion in chromosome 1q21.1 
c.-21G>A (rs139428292, in 
homozygosis) 
Confirmed  
[CNV in ANKRD26  
and c.2054C>T, p.(Pro685Leu) in 
MYH9] 
Excluded from CNVs control 
samples†† 
This study 
IT19 M PBC RBM8A RBM8A 
deletion in chromosome 1q21.1 
c.-21G>A (rs139428292, in 
homozygosis) 
Confirmed This study 
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IT20 M PBC ANKRD26, 
RUNX1 RUNX1 c.967+2_5del 
False negative# [c.2473+53C>A in 
NBEAL2] This study 
IT21 F PBC MYH9 MYH9 c.5797C>T, p.(Arg1933*) Confirmed [c.6798+11G>A in VWF] This study 
┼PBC, peripheral blood cells 
╪ Nucleotide A of the ATG translation initiation start site of the ACTN1, ANKRD26, c-MPL, CYCS,GATA1, GP1BA,GP1BB, ITGB3,MYH9, NBEAL2, RBM8A, RUNX1 cDNAs from 
GenBank sequences NM_001102.3, NM_014915.2, NM_005373.2, NM_018947.5, NM_002049.3, NM_000173.5, NM_000407.4, NM_000212.2, NM_002473.4, NM_015175.2, 
NM_005105.3, NM_001001890.2, respectively is indicated as nucleotide +1. In square brackets are potential pathogenetic heterozygous variants identified in genes different from 
that causing the disease. 
§ Mutation localized in amplicon AMPL 410828843 not covered by IPGM sequencing. 
ۅ Mutation localized in a region of GP1BB gene not covered by IPGM primer design 
¶
 Mutation localized at the end of the amplicon AMPL1254778695, region where the coverage drops reducing sequencing reliability. Mutation was not called by the TSVC because 
seen only 56 of 173 reads. 
#
 Mutation localized in a region where the reverse and forward primers of two adjacent amplicons aligned, reducing sequence efficiency of this mutant allele. Mutation was not called 
by the TSVC because seen only  
††
 These samples were excluded from CNVs control samples because of their low coverage uniformity (Table 15) 
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TABLE 3:QUALITY CONTROL DATA OF 30 FA SAMPLES ACCORDING TO IPGM ANALYSIS. 
Sample 
N. of bases 
per sample* 
Bases with 
Q≥ 20 
(%)┼ 
Mapped readsۋ 
Reads on target 
(%)§ 
Average reads 
per ampliconۊ 
Uniformity 
of amplicon 
coverage 
(%)¶ 
Amplicons 
reading       
end-to-end 
(%)# 
W1 108,116,974 89.6 781,876 97.4 1,099 96.8 71.4 
W2 75,262,526 80.9 603,475 95.0 828 97.3 29.7 
P3 35,785,078 82.7 267,284 97.4 375 49.2 18.8 
P4 119,723,202 82.7 895,474 97.6 1,261 86.9 36.1 
P5 70,204,308 85.2 521,101 96.1 722 96.5 52.7 
P6 46,370,665 87.9 332,419 97.0 465 95.2 66.4 
P7 91,330,404 83.2 680,112 97.1 953 96.5 38.1 
P8 114,403,621 85.5 856,185 94.9 1,172 96.8 51.1 
P9 78,309,348 90.1 564,085 97.5 793 97.9 77.1 
P10 39,666,030 83.0 304,766 95.7 421 95.4 42.9 
P11 50,060,326 80.6 403,472 93.6 546 97.3 29.4 
P12 49,900,000 89.6 370,530 95.1 509 96.3 75.5 
P13 96,878,877 80.8 784,389 95.5 1,082 94.2 29.3 
P14 64,792,636 84.6 490,221 93.4 660 96.5 45.6 
P15 170,110,091 90.1 1,226,673 98.5 1,743 93.5 72.6 
P16 61,705,451 86.5 468,489 92.1 623 97.7 68.4 
P17 81,994,349 84.8 603,842 96.8 843 96.8 52.0 
P18 80,418,943 84.7 607,565 94.4 827 97.8 44.6 
P19 47,553,650 80.3 384,555 94.4 525 96.8 26.7 
P20 23,598,575 87.7 170,190 97.1 238 96.1 67.8 
P21 84,534,746 84.8 634,677 91.2 835 97.3 48.3 
P22 14,437,622 82.7 112,325 95.8 155 97.6 40.7 
P23 127,535,800 85.7 914,955 97.3 1,284 96.3 59.6 
P24 30,683,292 84.9 225,630 96.6 314 96.7 54.3 
P25 57,285,000 84.8 423,405 96.0 587 96.7 53.4 
P26 74,338,167 85.0 560,816 95.7 774 96.0 46.9 
P27 46,719,940 80.8 377,211 95.9 523 97.3 28.4 
P28 56,726,182 87.9 407,532 96.7 967 95.5 74.3 
P29 78,923,835 81.2 631,032 95.6 873 98.0 30.7 
P30 43,969,366 85.0 334,231 94.0 453 96.8 45.2 
Min 14,437,622 80.3 112,325 91.2 155 49.2 18.8 
Max 170,110,091 90.1 1,226,673 98.5 1,743 98.0 77.1 
Mean 68,751,834 84.8 518,053 95.7 748 94.7 49.3 
St.dev 32,789,486 2.9 240,79 16.8 350 8.8 16.8 
Median 64,792,636 84.8 490,221 95.9 748 96.7 47.6 
1st quartile 46,719,940 82.7 370,530 94.9 512 96.0 36.6 
3rd quartile 81,994,349 86.3 631,032 97.0 933 97.3 64.7 
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*Total number of filtered and trimmed reads independent of length post filtering bases per barcode. 
┼The percentage of reads that have a predicted quality score of Q20 or better. A Q20 score is the predicted quality 
of a Phred-like score of 20 or better, or one error in 100 bp. 
ۆTotal number of reads mapped to the reference. 
§The percentage of reads mapped to any targeted region relative to all reads mapped to the reference. 
ۅThe average number of reads assigned to amplicons. The average number of reads assigned to amplicons. 
¶
 The percentage of bases in all targeted regions covered by at least 0.2x the average base read depth. 
#The percentage of all amplicons that were considered to have a sufficient proportion of assigned reads (70%) 
that covered the whole amplicon target from 'end-to-end'. To allow for error the effective ends of the amplicon 
region for read alignment are within 2 bases of the actual ends of the region. 
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TABLE 4:AMPLICONS NOT COVERED MORE THAN 30X IN FA SAMPLES 
Gene Exon ID amplicons 
N. of samples 
with coverage <30X 
FANCA 
1 AMPL544050257a 15 (including P29a) 
6 AMPL544193477 1 (P28)b 
7 AMPL2671673445 2 
12 AMPL544284467 5 
15 
AMPL544674964 1 (P4)c 
AMPL544681421 1 (P4)c 
16 AMPL544342332 1 
FANCB 
3 AMPL544417387 4 
4 
AMPL1197148282d 12 
AMPL544382746 1 
FANCC 4 AMPL592054836 5 
FANCD1 
8 AMPL388297720 1 
11 
AMPL388360704 1 
AMPL404630568d 10 
AMPL658814386 2 
16 AMPL624416753 6 
20 AMPL388340296d 21 
FANCD2 
17 AMPL434371586 4 
26 AMPL442020299 1 
FANCE 10 AMPL544603911 1 
FANCG 6 AMPL543852913 5 
FANCI 
11 AMPL1190859878 1 
32 AMPL544478748 2 
FANCJ 
8 AMPL416725112 7 
11 AMPL414710255 6 
15 AMPL434475581 1 
17 AMPL433543078d 15 
FANCL 1 AMPL543889772 1 
FANCM 
5 AMPL1156281934 3 
6 AMPL544176673 2 
14 AMPL2595994868 1 
18 AMPL1104380167 1 
19 AMPL1103979554 6 
19 AMPL1157014550 1 
FANCP 14 AMPL544488815 2 
aGC-rich region; in P29 Sanger sequence 
revealed a pathogenetic c.50dup mutation; 
bIn P28, amplicon was deleted on one allele 
and not amplified on the other for allelic 
drop-out  (c.548G>A present on one primer 
complimentary sequence); 
cP4 had two large genomic deletion of 
FANCA encompassing exon 15; 
dSelf-annealing or intra-strand loop formation 
were likely to be responsible for low 
amplicon coverage. 
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TABLE 5:TRUE POSITIVE (TP) VARIANTS IDENTIFIED ON FA SAMPLES IN VALIDATION II. 
Number Gene TP variants┼ 
rs number 
(MAF in 1000 
Genome databse) 
Pathogenicity 
N. of samples 
with TP 
(Sample with 
pathogenetic 
variant) 
1 
FANCA 
(NM_000135.2) 
c.548G>A p.(Trp183*) nr nonsense 1 (P28) 
2 
c.826+3del 
p.(250_251insGlyAla 
PheMetThrArgCysGlyPheLeu) 
nr 
splicing 
(in frame)§ 1 (P26) 
3 c.1776+7A>G p.(Ile573Serfs*12) nr 
splicing 
(frameshift)§ 1 (P27) 
4 c.3660del p.(Asn1221Thrfs*26) nr 
small deletion 
(frameshift) 1 (P29) 
5 c.3788_3790del p.(Phe1263del) nr 
small deletion 
(in frame) 1 (P26) 
6 c.4260+29T>C rs1800359 (0.18) nd 1 
7 c.4332T>G p.(=) rs149531696 (nr) synonym 1 
8 FANCB (NM_001018113.1 ) 
c.147A>G 
p.(=) nr 
synonym 
(donor splice site - 
score 68)╪ 
1 
9 
FANCC 
(NM_000136.2) 
c.37C>T 
p.(Gln13*) rs121917784 (nr) nonsense 2 (P22, P23) 
10 
c.67del 
p.(Asp23Ilefs*23) 
homozygous 
rs104886459 (nr) small deletion (frameshift) 1 (P21) 
11 c.554G>A p.(Arg185Gln) rs370346767 (nr) missense (1)╪ 1 
12 c.692_694del p.(Lys231del) rs3831244 (nr) small deletion (in frame) 1 (P22) 
13 c.816C>T p.(=) rs55719336 (<0.01) synonym 1 
14 c.1069C>T p.(Gln357*) nr nonsense 1 (P23) 
15 
FANCD1 
(NM_000059.3) 
c.800G>A p.(Gly267Glu) rs80359036 (nr) missense (0)╪ 1 
16 c.1114A>C p.(Asn372His) rs144848 (0.24) missense (2)
╪
 1 
17 c.1151C>T p.(Ser384Phe) rs41293475 (nr) missense (5)╪ 1 (P18) 
18 c.1938C>T p.(=) rs28897711 (<0.01) synonym 1 
19 c.4258G>T p.(Asp1420Tyr) rs28897727 (<0.01) missense (2) ╪ 1 
20 c.8755-66T>C rs4942486 (0.47) nd 1 
21 c.8953+98T>C rs81002901 (<0.01) nd 1 
22 c.9875C>T p.(Pro3292Leu) rs56121817 (<0.01) missense (8)╪ 1 (P23) 
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23 
FANCD2 
(NM_001018115.1) 
c.65-18A>C nr nd 1 
24 c.784-27del nr nd (acceptor splice site 
- score 68)╪ 1 
25 c.1634A>G p.(Asn545Ser) rs145522204 (<0.01) missense (2)╪ 2 
26 c.2021+31C>T rs3864015 (nr) nd 11 
27 c.2103G>T p.(=) rs139033444 (nr) synonym 1 
28 c.2204G>A p.(Arg735Gln) nr missense (8)╪ 1 (P11) 
29 c.2269+15C>T nr nd 1 
30 c.2606-40A>T rs36075953 (<0.01) nd 1 
31 c.2977-39C>T rs45622438 (<0.01) nd 1 
32 c.3336-74G>A rs34197804 (<0.01) nd 1 
33 FANCE (NM_021922.2) 
c.1572G>A 
p.(=) rs115195341 (<0.01) synonym 1 
34 
FANCF 
(NM_022725.3) 
c.484_485del 
p.(Leu162Aspfs*103) 
homozygous 
nr 
small deletion 
(frameshift) 1 (P24) 
35 c.557C>T p.(Ala186Val) rs113910234 (<0.01) missense (0)╪ 1 
36 
FANCG 
(NM_004629.1) 
c.1538G>A p.(Arg513Gln) rs17885240 (<0.01) missense (0)╪ 2 (P17, P24) 
37 c.1636+7A>G rs587118 (0.25) nd 1 
38 
FANCI 
(NM_001113378.1) 
c.755+55G>A rs183255195 (<0.01) nd (donor splice site -
score 66)╪ 1 
39 c.976-125 T>C nr nd 1 
40 c.1963G>A p.(Gly655Arg) rs138026584 (nr) missense (3)╪ 2 
41 c.1992+10T>C nr nd 1 
42 c.2203A>G p.(Ile735Val) nr missense (0)╪ 1 
43 c.2225G>C p.(Cys742Ser) rs2283432 (0.29) missense (1)╪ 1 
44 c.2292-120T>C rs11855524 (0.07) nd 1 
45 c.2367G>T p.(=) rs11857960 (0.08) synonym 1 
46 
FANCJ 
(NM_032043.2) 
c.1466T>C p.(Ile489Thr) nr missense (7)╪ 1 (P7) 
47 c.2286T>C p.(=) rs61754141 (<0.01) synonym 1 
48 c.2906-31A>G nr nd (acceptor splice site 
- score71)╪ 1 
49 
FANCL 
(NM_018062.3) 
c.50C>G 
p.(Pro17Arg) nr missense (8)
╪
 2 (W2, P30) 
50 c.676C>T p.(Arg226Cys) nr missense (8)╪ 1 (P30) 
51 c.1021T>A p.(Trp341Arg) nr missense (8)╪ 1 (P30) 
52 c.1096_1099dup p.(Thr367Asnfs*13) nr 
smallinsertion 
(frameshift) 1 (P8) 
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53 
FANCM 
(NM_020937.2) 
c.171G>C p.(Leu57Phe) rs142007602 (<0.01) missense (4)
╪
 1 
54 c.874C>G p.(Pro292Ala) rs142747831 (<0.01) missense (6)
╪
 1 (P20) 
55 c.1249G>T p.(Glu417*) nr nonsense 1 (P7) 
56 c.1397-58T>G rs11157433 (0.24) nd (acceptor splice 
site - score 77)╪ 2 
57 c.1397-16_1397-14del nr nd 2 
58 c.5848T>G p.(Leu1950Val) rs146436929 (<0.01) missense (6)
╪
 1 (P20) 
59 
FANCN 
(NM_024675.3) 
c.2586+58C>T rs249954 (0.34) nd 1 
60 c.2586+81C>T rs114710547 (<0.01) nd 1 
61 c.2587-38C>G rs180177119 (nr) nd 1 
62 c.2816T>G p.(Leu939Trp) rs45478192 (<0.01) missense (8)╪ 1 (P17) 
63 FANCO (NM_058216.2) c.790G>A p.(Gly264Ser) rs147241704 (nr) missense (3)
╪
 1 
64 
FANCP 
(NM_032444.2) 
c.590T>C p.(Val197Ala) rs147826749 (<0.01) missense (0)
╪
 1 
65 c.753G>A  p.(=) rs8061528 (0.25) synonym 1 
66 c.4580C>T p.(Pro1527Leu) rs149362820 (nr) missense (0)╪ 1 
67 c.5501A>G p.(Asn1834Ser) rs111738042 (<0.01) missense (0)
╪
 1 
Total TP variants 83 
┼TP (true positive) variants are all heterozygous except for mutation #34. Nucleotide A of the ATG translation 
initiation start site of the cDNAs from reference sequence is indicated as nucleotide +1. In gray, pathogenetic 
variants of the disease-causing gene. In darker gray, heterozygous potential pathogenetic variants in a gene 
different from that causing the disease. 
╪Effect of the missense variations was evaluated using four pathogenicity prediction programs, Mutation Taster, 
Mutation Assessor and SIFT. and of intronic variants using Human Splicing Finder Version 2.4.1 (see Materials 
and Methods). 
§Confirmed by RT-PCR by De Rocco at al (2014) 
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TABLE 6:FALSE POSITIVE (FP) VARIANTS IDENTIFIED ON FA SAMPLES IN VALIDATION II 
Number Gene FP variants┼ 
rs number 
(MAF in 1000 Genome Database) 
Status 
N. of 
samples 
with FP 
Sequence contest of FP╪ 
1 FANCC (NM_000136.2) c.1297del not reported homozygous 6 GCCCCCGTGATGGG 
2 
FANCD2 
(NM_001018115.1) 
c.696-19C>T not reported heterozygous 1 CTTTTTTCTTTTTCT 
3 c.1134+39T>G not reported heterozygous 1 CAGACTTAAAAGTA 
4 c.1170C>T rs1122887807 (not reported) heterozygous 25 TAGCACCAATACTCAGACAAA 
5 c.1179T>C rs72492998 (not reported) heterozygous 25 TAGCACCAATACTCAGACAAA 
6 c.1214A>G rs73126218 (not reported) heterozygous 25 CTAAGAAATAAGAT 
7 c.2715+96A>T not reported heterozygous 1 GAAAAAAAAATTAG 
8 
FANCE (NM_021922.2) 
c.970-26T>G rs192832780 (0.0009) heterozygous 1 TCCCGGTGTCCTCTCTCCCCCC 
9 c.1113+23_1113+24insC not reported (0.0018) heterozygous 1 TGGGAGGTACTC(C)AGAGTGCCAAG 
10 FANCI 
(NM_001113378.1) 
c.3537+41C>A not reported heterozygous 1 TTCTACCCCAGT 
11 c.3947G>A rs138461165 (0.0005) heterozygous 1 ATGGGGGACAGAA 
12 
FANCJ (NM_032043.2) 
c.1543G>T not reported heterozygous 2 GCAAGAGAAGTA 
13 c.2575+8C>A not reported heterozygous 22 GATCTCAGCTGGG 
14 
FANCL (NM_018062.3) 
c.375-26A>T not reported heterozygous 3 GATCATTTTTTATTC 
15 c.375-25T>A not reported heterozygous 4 GATCATTTTTTATTC 
16 FANCM (NM_020937.2) c.1397-16_1397-14del not reported homozygous 1 TTAAAGTTTTTATATATATATATAG 
17 
FANCP 
(NM_032444.2) 
c.3661del not reported homoztgous/ heterozygous 2 GAGGGGGCGCTGCC 
18 c.4259C>A n not reported r heterozygous 1 GACAGTGACCCCCCAATTCCAATTGAC 
19 c.4261A>C not reported heterozygous 1 GACAGTGACCCCCCAATTCCAATTGAC 
Total FP annotations 124  
┼
 Nucleotide A of the ATG translation initiation start site of the cDNAs from reference gene sequence is indicated as nucleotide +1. 
╪ In bold are the nucleotide changes. 
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TABLE 7:MANN-WHITNEY TEST BETWEEN FA MALES AND FA FEMALES 
Sample Gender 
P 
(FANCB sample / FANCB ♀ control) 
P 
(FANCB sample / FANCB ♂ control) 
All males ♂ <.0001 1 
All females ♀ 1 <.0001 
P12 ♂ <.0001 .0926 
P26 ♂ <.0001 .9992 
P14 ♂ <.0001 .3974 
P15 ♂ <.0001 .8992 
P13 ♂ <.0001 1 
P25 ♂ <.0001 .9237 
P7 ♂ <.0001 .7416 
W1 ♂ <.0001 .746 
P5 ♂ <.0001 .7212 
P8 ♂ <.0001 .6867 
P20 ♂ <.0001 .8686 
P30 ♂ <.0001 .3058 
P16 ♂ <.0001 .0477 
P28 ♀ .016 <.0001 
P10 ♀ .1654 <.0001 
P11 ♀ .0902 <.0001 
P18 ♀ .3932 <.0001 
P6 ♀ .2542 <.0001 
P21 ♀ .8961 <.0001 
P27 ♀ .9754 <.0001 
W2 ♀ .9187 <.0001 
P24 ♀ .7117 <.0001 
P4 ♀ .5231 .0011 
P23 ♀ .4632 <.0001 
P9 ♀ .1809 <.0001 
P29 ♀ .7117 <.0001 
P19 ♀ .7958 <.0001 
P17 ♀ .0775 <.0001 
P22 ♀ .0001 <.0001 
To exclude that the difference observed between males and females was due to random variations of the FANCB 
coverage, the Mann-Whitney test (distribution of the data was non-normal) was performed. Samples were split in 
two control groups (males and females) against which we compared all the intersample normalisation ratios of 
FANCB amplicons of each patient. The difference between median of all patients and the median of controls of the 
opposite gender was statistically significant, while the difference between median of all patients and the median of 
true gender was not significant, except in samples P16, P22, and P28. Male P16 has a significantly higher median 
(median=0.56; IQR=0.52-0.62) than the median of male population (median=0.52; IQR=0.44-0.62). Females P22 
and P28 had a significantly higher (median=1.28; IQR=1.16-1.41) and lower (median=0.91; IQR=0.78-1.13) 
median than that of the female population (median=1.05; IQR=0.90-1.24) (Figure 6). 
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Table 8:QUALITY CONTROL DATA OF 21 IT SAMPLES ACCORDING TO IPGM ANALYSIS. 
Sample N. of bases per 
sample* 
Bases with Q≥ 20 
(%)┼ 
Mapped 
readsۆ 
Reads on 
target (%)§ 
Average 
reads per 
ampliconۅ 
Uniformity 
of amplicon 
coverage 
(%)¶ 
Amplicons 
reading      
end-to-end 
(%)# 
IT1 48,614,966 76.88 380,196 76.50 447.5 80.46 10.92 
IT2 110,190,830 84.26 713,456 78.1 857.3 90.62 31.54 
IT3 161,154,396 75.96 1,302,367 84.34 1,690 89.38 8.15 
IT4 40,935,105 78.11 309,174 78.53 373.5 84.8 12 
IT5 42,371,873 83.85 276,771 71.48 304.4 91.38 32.46 
IT6 22,019,831 88.25 149,242 51.02 117.1 91.63 48.92 
IT7 171,185,275 83.87 1,100,647 78.51 1,329 87.85 31.69 
IT8 62,379,030 85.66 419,581 79.67 514.3 72.97 32.77 
IT9 66,773,457 76.50 531,704 80.71 660.2 92 8.15 
IT10 51,723,151 75.98 412,712 87.14 553.3 82.57 8.31 
IT11 139,139,962 84.02 899,608 73.4 1,016 91.85 33.85 
IT12 41,683,159 88.23 248,823 74.14 283.8 91.92 48.15 
IT13 54,731,660 76.13 435,859 85.53 573.5 90.46 7.85 
IT14 63,099,005 77.34 490,446 65.63 495 91 11.38 
IT15 175,304,921 77.52 1,330,528 82.28 1,685 90 11 
IT16 19,007,723 84.06 121,246 88.85 165.7 83.8 33.69 
IT17 84,513,720 77.82 644,389 84.35 836.2 89.38 11.08 
IT18 40,613,036 84.24 262,707 79.02 319.4 72.48 33.08 
IT19 76,364,384 84.71 489,140 87.16 655.9 87.69 32.15 
IT20 76,286,614 76.16 606,098 82.78 771.9 87.54 8.77 
IT21 54,890,008 84.08 357,874 66.72 367 92.32 31 
Min 19,007,723 75.96 121,246 51.02 117.1 72.48 7.85 
Max 175,304,921 88.25 1,330,528 88.85 1,690 92.32 49 
Mean 76,332,481 81.13 546,789 77.90 667.45 87.23 23.21 
St. dev 47,447,684 4.38 347,263 8.84 445.55 5.86 13.96 
Median 62,379,030 84 435,859 79 553 89 31 
1st quartile 42,371,873 76.88 309,174 74.14 367.3 84.80 10.92 
3rd quartile 84,513,720 84.24 644,389 84.34 836.2 91.38 32.77 
*Total number of filtered and trimmed reads independent of length post filtering bases per barcode. 
┼The percentage of reads that have a predicted quality score of Q20 or better. A Q20 score is the predicted quality 
of a Phred-like score of 20 or better, or one error in 100 bp. 
ۋTotal number of reads mapped to the reference. 
§The percentage of reads mapped to any targeted region relative to all reads mapped to the reference. 
ۊThe average number of reads assigned to amplicons. The average number of reads assigned to amplicons. 
¶
 The percentage of bases in all targeted regions covered by at least 0.2x the average base read depth. 
#The percentage of all amplicons that were considered to have a sufficient proportion of assigned reads (70%) 
that covered the whole amplicon target from 'end-to-end'. To allow for error the effective ends of the amplicon 
region for read alignment are within 2 bases of the actual ends of the region. 
  
 54 
Table 9: AMPLICONS NOT COVERED MORE THAN 30X IN IT SAMPLES 
Gene Exon ID amplicons N. of samples with coverage 
<30X 
ABCG5 
3 AMPL5119879043 4 
4 AMPL1852930860* 20 
7 AMPL5119952114‡ 12 
ACTN1 
1 AMPL476202878† 21 
12 AMPL469584238‡ 12 
ANKRD26 
1 AMPL5120483301 4 
3 AMPL680614872 4 
24 AMPL3819594782 3 
24 AMPL3819794179 8 
24 (i) AMPL4037050642 5 
28 AMPL3817684916 5 
29 (i) AMPL4037001163 4 
FLNA 
1 AMPL1528530537 16 
6/7 AMPL1525570810 4 
24 AMPL4041039780* 21 
39 AMPL1524945354 8 
41 AMPL1528095906 4 
47 AMPL891610539 3 
GATA1 
1 AMPL547618158‡ 21 
2 AMPL5119257697 3 
5 AMPL5119891818* 21 
5 AMPL547636375* 21 
GP1BA 
1 AMPL2608384287‡ 21 
1 AMPL5120151981 10 
GP1BB 
1 AMPL5120107016* 21 
1 AMPL5120137731* 10 
1 AMPL5120138512 21 
GP9 1 AMPL5102829037
* 21 
1 AMPL5120134312* 20 
HOXA11 1 AMPL1617532402* 19 
ITGA2B 
5 AMPL2606141536 4 
20 AMPL5120255688 6 
21 AMPL3949052660 4 
27 AMPL2605653688‡ 13 
MPL 
1 AMPL3877386620 4 
3 AMPL410828843* 21 
7 AMPL405671894 3 
9 AMPL5119412286 9 
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MYH9 
1 AMPL5120268995‡ 15 
5i AMPL763436336 3 
23 AMPL762419900 7 
24 AMPL1801239905 3 
27 AMPL5119178104 5 
29 AMPL763222728 7 
29 AMPL763233917* 21 
NBEAL2 
1 AMPL3762892822 5 
3 AMPL5119619893 4 
16 AMPL5119576873 4 
26 AMPL2607417535 4 
33 AMPL2579769787 3 
36 AMPL2608128223* 21 
53/54 AMPL2585118671* 20 
54 AMPL5102380983* 16 
RUNX1 
5'utr AMPL736666055* 18 
6 AMPL5116682733* 18 
WAS 10 AMPL5119468679* 21 
*Amplicons covered less than 30X because of potential self-annealing or intra-strand loop formation of primers. 
†Amplicons characterized by the presence of a GC rich region (AMPL476202878, 77%) an repetitive sequences 
(AMPL5120138512),  which interfere with the amplification efficiency. 
‡Amplification efficiency is influenced by the Temperature of Annealing that results higher than used for the 
amplification reaction used for the library preparation 
For the remaining amplicons the efficiency of amplification is worse than that of the other amplicons, thus when 
the overall efficiency of the libraries is low, the amplicon coverage become <30X 
.  
  
 56 
Table 10: IT RARE VARIANTS (MAF<0.01) CONSIDERED IN THE STUDY. 
No Gene variant analyzed┼ 
rs number (MAF in 
1000 Genome 
databse) 
Pathogenicity N. of samples with 
variant 
Confirmed by 
Sanger 
sequencing 
 
1 ABCG5 (NM_022436.2) c.1878T>C p.(=) nr synonym (0) 1 not analyzed  
2 
ABCG8 
(NM_022437.2) 
c.1924G>A p.(Ala642Thr) rs113005049 (nr) missense (1) 1 not analyzed 
 
3 c.1212-7T>A nr splicing 1 (IT4) yes 
 
4 c.1941C>G p.(=) rs147991100  (nr) synonym (2) 1 not analyzed 
 
5 c.1201A>T p.(Thr401Ser) rs144200355 (0.0006) missense (4) 1 not analyzed  
6 
ACTN1 
(NM_001102.3) 
c.751G>A p.(Gly251Arg) nr missense (7) 1  (known mutation in 
IT1) yes  
7 c.1385+89A>C rs566944399 (<0.01) 
generation of new potential 
acceptor splice site: score 67.04 1 (IT14) yes  
8 c.2210C>A p.(Thr737Asn) nr missense (7) 1 (known mutation in 
IT2) yes  
9 c.2133+44del nr deletion (controlla patogenicità) 6 no 
 
10 
ANKRD26 
(NM_014915.2) 
c.-127A>T nr present in public mutation database§ 
1 (known mutation in 
IT3) yes  
11 c.-134G>A nr present in public mutation database§ 
1 (known mutation in 
IT4) yes  
12 c.1269+7T>A rs201014646 (nr) no differences between wt and mut 1 not analyzed 
 
13 c.1461+26G>C nr no differences between wt and mut 1 not analyzed 
 
14 c.4086-80A>G nr no differences between wt and mut 1 not analyzed 
 
15 CYCS (NM_018947.5) c.154G>A p.(Ala52Thr) 
rs573366932 
(<0.01) missense (7) 
1 (known mutation in 
IT7) yes  
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16 
FLNA 
(NM_001110556.
1) 
c.355A>G p.(Ile119Val) nr missense (5) 3 no 
 
17 c.1567+45delC nr small deletion 3 no 
 
18 c.3980-34C>G nr no differences between wt and mut 1 not analyzed 
 
19 c.6735C>G p.(=) nr synonym (2) 8 not analyzed 
 
20 c.7686C>T p.(=) rs76337075 (nr) synonym (2) 1 not analyzed 
 
21 c.7157-35_37del nr deletion 7 no 
 
22 GATA1 (NM_002049.3) c.647G>A p.(Arg216Gln) rs104894809 (nr) 
missense present in public 
mutation database‡  
1 ( known mutation in 
IT8) yes  
23 
GP1BA 
(NM_000173.5) 
c.92T>C p.(Val31Ala) rs201827537 (nr) missense (4) 1 not analyzed 
 
24 c.104del p.(Lys35Argfs*4) nr present in public database¤ 1(known mutation in 
IT9) yes  
25 c.206C>T p.(Pro69Leu) rs138825640  (0.0008) missense (1) 1 not analyzed  
26 c.1806T>G p.(=) nr synonym (2) 4 not analyzed 
 
27 GP1BB (NM_000407.4) c.47T>C p.(Leu16Pro) nr 
missense present in public 
mutation database¤ 
1 (known mutation in 
IT10) yes  
28 GP9 (NM_000174.3) c.236C>T p.(Thr79Ile) 
rs200640594  (<0.0
1) missense (0) 1 not analyzed  
29 HOXA11 (NM_005523.5) c.455A>G p.(Glu152Gly) nr missense (4) 1 not analyzed  
30 
ITGA2B 
(NM_000419) 
c.998G>T p.(Gly333Val) nr missense (9) 2 no 
 
31 c.2602G>A p.(Val868Met) rs74988902 (<0.01) missense (4) 1 not analyzed 
 
32 c.2613del p.(Leu872Cysfs*38) nr frameshift 1 no 
 
33 ITGB3 
(NM_000212.2) 
c.2134+1G>C rs398122373 (nr) present in public mutation database‡ 
1 (known mutation in 
IT12) yes  
34 c.2184G>A p.(=) rs376459842 (nr) synonym (2) 1 not analyzed 
 
35 
MPL 
(NM_005373.2) 
c.235_236del p.(Leu79Glufs*84) nr present in public mutation database* 
1 (known mutation in 
IT6) yes  
36 c.1653delG p.(Lys553Argfs*77) nr present in public mutation database#  
1 (known mutation in 
IT6) yes  
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37 
MYH9 
(NM_002473.4) 
c.230C>G p.(Pro77Arg) nr missense (9) 1 no 
 
38 c.705+11C>T rs201738304 (<0.01) no differences between wt and mut 1 not analyzed  
39 c.1083C>T p.(=) rs56001030 (<0.01) synonym (0) 1 not analyzed 
 
40 c.2054C>T p.(Pro685Leu) nr missense (7)  1 (IT18) yes 
 
41 c.2114G>A p.(Arg705His) rs80338828 (nr) missense present in public 
mutation database‡  
2 ( known mutation in 
IT14 and IT15) yes  
42 c.3837+24C>T nr no differences between wt and mut 2 not analyzed 
 
43 c.4270G>A p.(Asp1424Asn) rs80338831 (nr) present in public mutation database¶ 1 no  
44 c.4359G>A p.(=) rs202127454 (<0.01) synonym (2) 1 not analyzed  
45 c.5026A>G p.(Lys1676Glu) rs138158369 (nr) missense (7) 1 (IT14) yes 
 
46 c.5143G>A p.(Gly1715Ser) rs148109368 (<0.01) missense (5) 1 (IT5) yes  
47 c.5521G>A p.(Glu1841Lys) rs80338834 (nr) missense present in public 
mutation databaseۅ  
1 (known mutation in  
IT16) yes  
48 c.5393A>C p.(Glu1798Ala) nr missense (8) 14 no 
 
49 c.5797C>T p.(Arg1933*) rs80338835 (nr) nonsense present in public 
mutation databaseۅ  
1 ( new mutation found 
in IT21) yes  
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50 
NBEAL2 
(NM_015175.2) 
c.1898+33C>T rs201762779 (<0.01) 
generation of new potential donor 
splice site: score 77.42 1 (IT12) yes  
51 c.2187C>A p.(Tyr729*) nr nonsense 1 (known mutation in  
IT17) yes  
52 c.2473+53C>A nr 
generation of new potential 
acceptor splice site: score 78.24/ 
potential loss of acceptor splice 
site: score 63.75 
3 (IT10, IT4, IT20) yes 
 
53 c.2556+33G>A rs201426707 (0.0004) no differences between wt and mut 1 not analyzed  
54 c.4530G>C p.(Glu1510Asp) nr missense (3) 1 not analyzed 
 
55 c. 8027+5G>C nr 
potential loss of acceptor splice 
site, score:39.47/potential loss of 
donor site, score:74.8 
3 no 
 
56 8027+6C>G nr generation of new potential 
acceptor site, score:72.58 2 no  
57 RBM8A (NM_005105.3) c.67+32G>C nr 
present in public mutation 
database¶  1 ( IT9) yes  
58 RUNX1 (NM_001001890.
2) 
c.270+95delT rs568042691 (<0.01) 
generation of a new potential 
acceptor site, score:71.91/ potential 
loss of acceptor site, score: 41.97/ 
generation of new potential donor 
site, score: 66.48 
1 (IT5) yes 
 
59 c.725-48A>T nr no differences between wt and mut 1 not analyzed 
 
60 TUBB1 (NM_030773) c.111C>T p.(=) 
rs150453159 
(<0.01) synonym (2) 1 not analyzed  
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61 
VWF 
(NM_000552.3) 
c.220+57del nr small deletion 1 no 
 
62 c.220+71G>A  rs531709650 (<0.01) 
potential loss of acceptor splice 
site, score:39.1 1 ( IT8) yes  
63 c.1614C>T p.(=) rs138268387 (<0.01) synonym (2) 1 not analyzed  
64 c.2821-41G>T rs113608895 (<0.01) no differences between wt and mut 1 not analyzed  
65 c.4195G>A p.(Arg1399His) rs1800382  missense (8) 1 no 
 
66 c.5049A>C p.(=) rs200368994  (nr) synonym (0) 1 not analyzed 
 
67 c.6303C>A p.(=) rs115914543 (<0.001) synonym (2) 1 not analyzed  
68 c.6798+11G>A rs139999346 (<0.01) 
generation of new potential 
acceptor splice site: score 72.53 1(IT21) yes  
60 c.7548+66C>G nr generation of new potential donor 
site, score: 73.86 1(IT8) yes  
70 WAS (NM_000377.2) c.1349-18G>A rs370010448 (nr) no differences between wt and mut 1 not analyzed  
§present in CLINVAR and OMIM 
‡present in CLINVAR, OMIM and HGVD 
*present in CLINVAR, HGMD and LOVD 
#present in HGMD 
ۅpresent CLINVAR, LOVD, OMIM and HGVD 
¶present in CLINVAR 
Red arrows indicate the 75 (40 different) variants validate with Sanger sequencing because considered potentially pathogenetic due to their presence in mutation database or their 
high pathogenicity score (see materials and methods). The 30 (27 different) pathogenetic variants confirmed by Sanger sequencing are highlighted in blue. 
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Table 11: MANN-WHITNEY TEST BETWEEN IT MALES AND IT FEMALES 
Sample Gender 
FLNA GATA1 WAS 
P (FLNA 
sample / 
FLNA ♂ 
control) 
P (FLNA 
sample / 
FLNA ♀ 
control) 
P (GATA1 
sample / 
GATA1 ♂ 
control) 
P (GATA1 
sample / 
GATA1 ♀ 
control) 
P (WAS 
sample / 
WAS ♂ 
control) 
P (WAS 
sample / 
WAS ♀ 
control) 
ALL MALE ♂ 1.0000 0.0000 1.0000 0.0000 1.0000 0.0000 
ALL FEMALE ♀ 0.0000 1.0000 0.0000 1.0000 0.0000 1.0000 
IT1 ♂ 0.0347 <0,0001 0.8341 0.0001 0.9033 <0,0001 
IT2 ♂ 0.0632 <0,0001 1.0000 0.0001 0.3721 <0,0001 
IT5 ♂ <0,0001 <0,0001 0.0594 0.0001 0.0305 <0,0001 
IT7 ♂ 0.0146 <0,0001 0.4980 0.0001 0.1555 <0,0001 
IT8 ♂ <0,0001 <0,0001 0.0501 0.0001 <0,0001 <0,0001 
IT9 ♂ 0.0274 <0,0001 0.4091 0.0001 0.0251 <0,0001 
IT10 ♂ <0,0001 <0,0001 0.6663 0.0001 0.6097 <0,0001 
IT14 ♂ 0.5737 <0,0001 0.9117 0.0001 0.4895 <0,0001 
IT17 ♂ 0.4005 <0,0001 0.6308 0.0001 0.4104 <0,0001 
IT18 ♂ <0,0001 <0,0001 0.6663 0.0086 0.2363 0.0001 
IT19 ♂ 0.2665 <0,0001 0.6843 0.0001 0.4386 <0,0001 
IT20 ♂ 0.0001 <0,0001 0.8534 0.0001 0.9363 <0,0001 
IT3 ♀ <0,0001 <0,0001 0.0001 0.4011 <0,0001 0.0473 
IT4 ♀ <0,0001 <0,0001 0.0001 0.4168 <0,0001 0.6275 
IT6 ♀ <0,0001 0.2821 0.0001 0.7726 <0,0001 0.5371 
IT11 ♀ <0,0001 0.3843 0.0001 0.6497 <0,0001 0.6331 
IT12 ♀ <0,0001 0.1439 0.0001 0.3019 <0,0001 0.8008 
IT13 ♀ <0,0001 0.0066 0.0001 1.0000 <0,0001 0.0173 
IT15 ♀ <0,0001 0.0035 0.0001 0.6497 <0,0001 0.2522 
IT16 ♀ <0,0001 <0,0001 0.0048 0.9014 <0,0001 0.3910 
IT21 ♀ <0,0001 0.1705 0.0001 0.7516 <0,0001 0.8370 
Since the distribution of the data was non-normal, we have performed a Mann-Whitney test to exclude that the 
difference observed between males and females was due to random variations of the FLNA, GATA1 and WAS 
coverage. For each gene, samples were split in two control groups (males and females) against which we 
compared all the intersample normalisation ratios of FLNA, GATA1 and WAS amplicons of each patient. The 
difference between median of all patients and the median of controls of the opposite gender was statistically 
significant, while the difference between median of all patients and the median of true gender was not significant, 
confirming the reliability of the attribution of gender test. 
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